

2026 AmeriHealth Caritas VIP Care FL (HMO-DSNP)

2026 Prior Authorization Criteria

CURRENT AS OF 01/01/2026

ACITRETIN

Products Affected

- acitretin*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	Prophylaxis of skin cancer in patients with previously treated skin cancers who have undergone an organ transplantation: approve. Psoriasis - Initial: the patient has documented trial of, contraindication to, or medical reason for not using at least 2 of the following treatments: topical steroids, tazarotene, methotrexate, and cyclosporine. Continuation of therapy: patient has positive clinical response to therapy.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

ACL INHIBITORS

Products Affected

- NEXLETOL
- NEXLIZET

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Primary Hyperlipidemia, Heterozygous Familial Hypercholesterolemia (HeFH) -Initial: [Note: documentation required] pt meets one of the following: (1) pt has untreated low-density lipoprotein cholesterol (LDL-C) level greater than or equal to 190 mg/dL at baseline OR (2) patient has genetic confirmation of HeFH by mutations in the low-density lipoprotein receptor, apolipoprotein B, proprotein convertase subtilisin kexin type 9 or low density lipoprotein receptor adaptor protein 1 gene OR (3) patient has been diagnosed with HeFH meeting one of the following diagnostic criteria thresholds: (i) the prescriber used the Dutch Lipid Network criteria and the patient has a score greater than 5 OR (ii) the prescriber used the Simon Broome criteria and the patient met the threshold for definite or possible familial hypercholesterolemia AND (4) pt tried or has contraindication to high intensity statin (i.e. minimum of atorvastatin 40 mg daily or rosuvastatin 20 mg daily or higher) AND LDL-C remains greater than or equal to 70 mg/dL unless the patient is determined to be statin intolerant (i.e. rhabdomyolysis or pt experienced skeletal related muscle symptoms while receiving separate trials of atorvastatin and rosuvastatin where symptoms resolved upon discontinuation of statin). Atherosclerotic Cardiovascular Disease (ASCVD) - Initial: (1) pt has one of the following conditions: prior MI, history of ACS, diagnosis of angina (stable or unstable), history of stroke or TIA, PAD, undergone a coronary or other arterial revascularization procedure AND (2) pt tried or has contraindication to high intensity statin (defined above) AND LDL-C remains greater than or equal to 70 mg/dL unless the patient is determined to be statin intolerant (defined above).
Age Restrictions	18 years of age or older.
Prescriber Restrictions	N/A
Coverage Duration	Request will be authorized until the end of the contract year.

PA Criteria	Criteria Details
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

ACTEMRA

Products Affected

- ACTEMRA ACTPEN
- ACTEMRA SUBCUTANEOUS

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent Use with a Biologic Disease-Modifying Antirheumatic Drug (DMARD) or Targeted Synthetic DMARD.
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with specialist for submitted diagnosis.
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	Polyarticular juvenile idiopathic arthritis (pJIA) - Initial: trial of, medical reason for not using, or contraindication to 2 of the following: Enbrel, an adalimumab product, or Xeljanz. Continuation of therapy: patient has been receiving Actemra for a minimum of 4 months and has positive response to treatment. Rheumatoid arthritis (RA): trial of, medical reason for not using, or contraindication to 2 of the following: Enbrel, an adalimumab product, or Xeljanz. Continuation of therapy: patient has been receiving Actemra for a minimum of 4 months and has positive response to treatment. Systemic juvenile idiopathic arthritis (sJIA), Giant Cell Arteritis and Systemic Sclerosis-Associated Interstitial Lung Disease: Approve.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

ACTIMMUNE

Products Affected

- ACTIMMUNE

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	Chronic granulomatous disease: prescribed by or in consultation with an hematologist, immunologist, or infectious disease specialist. Malignant osteopetrosis: prescribed by or in consultation with an endocrinologist or hematologist.
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	Chronic granulomatous disease - Initial: documented diagnosis confirming granulomatous disease. Continuation of therapy: patient does not show evidence of disease progression. Malignant osteopetrosis, severe infantile - Initial: documented diagnosis confirming severe, malignant osteopetrosis. Continuation of therapy: patient does not show evidence of disease progression.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

ADALIMUMAB

Products Affected

- *adalimumab-fkjp (2 pen)*
- *adalimumab-fkjp (2 syringe) subcutaneous prefilled syringe kit 20 mg/0.4ml, 40 mg/0.8ml*
- SIMLANDI (1 PEN) SUBCUTANEOUS AUTO-INJECTOR KIT 40 MG/0.4ML, 80 MG/0.8ML
- SIMLANDI (1 SYRINGE)
- SIMLANDI (2 PEN)
- SIMLANDI (2 SYRINGE) SUBCUTANEOUS PREFILLED SYRINGE KIT 20 MG/0.2ML, 40 MG/0.4ML

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off-Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

ADEMPAS

Products Affected

- ADEMPAS

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent use with Phosphodiesterase Inhibitors used for Pulmonary Hypertension or Other Soluble Guanylate Cyclase Stimulators.
Required Medical Information	Pulmonary arterial hypertension (PAH) (World Health Organization [WHO] Group 1)- Initial: [Note: documentation required] (1) PAH was confirmed by right heart catheterization AND (2) pretreatment mean pulmonary arterial pressure is greater than 20 mmHg AND (3) pretreatment pulmonary capillary wedge pressure is less than or equal to 15 mmHg, AND (4) pretreatment pulmonary vascular resistance is greater than or equal to 3 Wood units. Continuation of therapy: patient has positive clinical response to treatment. Chronic thromboembolic pulmonary hypertension (CTEPH) (WHO Group 4) - Initial: [Note: documentation required] (1) Patient has persistent or recurrent CTEPH after pulmonary endarterectomy (PEA) OR (2) patient has inoperable CTEPH with the diagnosis confirmed by right heart catheterization AND by computed tomography (CT), magnetic resonance imaging (MRI), or pulmonary angiography. Continuation of therapy: patient has positive clinical response to treatment.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a cardiologist or pulmonologist.
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

Formulary ID 26323

Last Updated: 10/15/2025

AIMOVIG

Products Affected

- AIMOVIG

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off-Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

ALPHA-1 PROTEINASE INHIBITORS

Products Affected

- ARALAST NP INTRAVENOUS SOLUTION RECONSTITUTED 1000 MG, 500 MG
- GLASSIA
- PROLASTIN-C INTRAVENOUS SOLUTION
- ZEMAIRA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Documentation of hereditary alpha1-antitrypsin deficiency as evident by (1) pretreatment serum AAT levels below 11 micromol/L (50 mg/dL by nephelometry or 80 mg/dL by radial immunodiffusion) AND (2) clinically evident emphysema (or chronic obstructive pulmonary disease).
Age Restrictions	N/A
Prescriber Restrictions	Prescriber by or in consultation with a pulmonologist.
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	Request for Glassia or Aralast NP: patient has a documented medical reason or contraindication for not using Prolastin-C or Zemaira.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

ALYFTREK

Products Affected

- ALYFTREK ORAL TABLET 10-50-125 MG, 4-20-50 MG

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent use with Trikafta, Kalydeco, Orkambi, or Symdeko. Patients with unknown CFTR gene mutations.
Required Medical Information	Documentation of CFTR gene that is responsive to vanzacaftor-tezacaftor-deutivacaftor treatment.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a pulmonologist or a provider who specializes in treatment of CF.
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	Cystic Fibrosis (CF) - Initial: patient must have at least one F508del mutation in the CFTR gene or a mutation in the CFTR gene that is responsive to the requested medication. Continuation of therapy: approve.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

AMBRISENTAN

Products Affected

- *ambrisentan*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Pulmonary arterial hypertension (PAH) (World Health Organization [WHO] Group 1) - Initial: [Note: documentation required] (1) PAH was confirmed by right heart catheterization AND (2) pretreatment mean pulmonary arterial pressure is greater than 20 mmHg AND (3) pretreatment pulmonary capillary wedge pressure is less than or equal to 15 mmHg, AND (4) pretreatment pulmonary vascular resistance is greater than or equal to 3 Wood units. Continuation of therapy: patient has positive clinical response to treatment.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a cardiologist or pulmonologist.
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

ANTINEOPLASTIC AGENTS

Products Affected

- *abiraterone acetate oral tablet 250 mg, 500 mg*
- ABIRTEGA
- AKEEGA
- ALECENSA
- ALUNBRIG ORAL TABLET 180 MG, 30 MG, 90 MG
- ALUNBRIG ORAL TABLET THERAPY PACK
- AUGTYRO ORAL CAPSULE 160 MG, 40 MG
- AVMAPKI FAKZYNJA CO-PACK
- AYVAKIT
- BALVERSA
- *bexarotene*
- BOSULIF ORAL CAPSULE 100 MG, 50 MG
- BOSULIF ORAL TABLET 100 MG, 400 MG, 500 MG
- BRAFTOVI ORAL CAPSULE 75 MG
- BRUKINSA ORAL CAPSULE
- BRUKINSA ORAL TABLET
- CABOMETYX
- CALQUENCE ORAL TABLET
- CAPRELSA ORAL TABLET 100 MG, 300 MG
- COMETRIQ (100 MG DAILY DOSE) ORAL KIT 80 & 20 MG
- COMETRIQ (140 MG DAILY DOSE) ORAL KIT 3 X 20 MG & 80 MG
- COMETRIQ (60 MG DAILY DOSE)
- COPIKTRA
- COTELLIC
- DANZITEN
- *dasatinib*
- DAURISMO ORAL TABLET 100 MG, 25 MG
- ENSACOVE
- ERIVEDGE
- ERLEADA ORAL TABLET 240 MG, 60 MG
- *erlotinib hcl oral tablet 100 mg, 150 mg, 25 mg*
- EULEXIN
- *everolimus oral tablet 10 mg, 2.5 mg, 5 mg, 7.5 mg*
- *everolimus oral tablet soluble*
- FOTIVDA
- FRUZAQLA ORAL CAPSULE 1 MG, 5 MG
- GAVRETO
- *gefitinib*
- GILOTRIF
- GOMEKLI
- HERNEXEOS
- IBRANCE
- IBTROZI
- ICLUSIG
- IDHIFA
- *imatinib mesylate oral tablet 100 mg, 400 mg*
- *imkeldi*
- INLYTA ORAL TABLET 1 MG, 5 MG
- INQOVI
- INREBIC
- ITOVEBI
- IWILFIN
- JAYPIRCA ORAL TABLET 100 MG, 50 MG
- KISQALI (200 MG DOSE)
- KISQALI (400 MG DOSE)
- KISQALI (600 MG DOSE)
- KISQALI FEMARA (400 MG DOSE)
- KISQALI FEMARA (600 MG DOSE)
- KOSELUGO ORAL CAPSULE
- KRAZATI
- *lapatinib ditosylate*
- LAZCLUZE
- *lenalidomide*
- LENVIMA (10 MG DAILY DOSE)
- LENVIMA (12 MG DAILY DOSE)
- LENVIMA (14 MG DAILY DOSE)
- LENVIMA (18 MG DAILY DOSE)

Formulary ID 26323

Last Updated: 10/15/2025

- LENVIMA (20 MG DAILY DOSE)
- LENVIMA (24 MG DAILY DOSE)
- LENVIMA (4 MG DAILY DOSE)
- LENVIMA (8 MG DAILY DOSE)
- LEUKERAN
- LONSURF
- LORBRENA ORAL TABLET 100 MG, 25 MG
- LUMAKRAS
- LYNPARZA ORAL TABLET
- LYTGOBI (12 MG DAILY DOSE)
- LYTGOBI (16 MG DAILY DOSE)
- LYTGOBI (20 MG DAILY DOSE)
- MEKINIST ORAL SOLUTION RECONSTITUTED
- MEKINIST ORAL TABLET 0.5 MG, 2 MG
- MEKTOVI
- *mercaptopurine oral suspension*
- MODEYSO
- NERLYNX
- *nilotinib d-tartrate oral capsule 150 mg, 200 mg, 50 mg*
- *nilotinib hcl oral capsule 150 mg, 200 mg, 50 mg*
- *nilutamide*
- NINLARO
- NUBEQA
- ODOMZO
- OGSIVEO ORAL TABLET 100 MG, 150 MG, 50 MG
- OJEMDA
- OJJAARA
- ONUREG
- ORGOVYX
- ORSERDU ORAL TABLET 345 MG, 86 MG
- *pazopanib hcl*
- PEMAZYRE
- PIQRAY (200 MG DAILY DOSE)
- PIQRAY (250 MG DAILY DOSE)
- PIQRAY (300 MG DAILY DOSE)
- POMALYST
- QINLOCK
- RETEVMO ORAL TABLET 120 MG, 160 MG, 40 MG, 80 MG
- REVLIMID
- REVUFORJ
- REZLIDHIA
- ROMVIMZA
- ROZLYTREK ORAL CAPSULE 100 MG, 200 MG
- ROZLYTREK ORAL PACKET
- RUBRACA
- RYDAPT
- SCEMBLIX ORAL TABLET 100 MG, 20 MG, 40 MG
- SOLTAMOX
- *sorafenib tosylate*
- STIVARGA
- *sunitinib malate*
- TABLOID
- TABRECTA
- TAFINLAR ORAL CAPSULE
- TAFINLAR ORAL TABLET SOLUBLE
- TAGRISSO
- TALZENNA
- TAZVERIK
- TEPMETKO
- THALOMID ORAL CAPSULE 100 MG, 50 MG
- TIBSOVO
- *toremifene citrate*
- *tretinoin oral*
- TRUQAP
- TUKYSA ORAL TABLET 150 MG, 50 MG
- TURALIO ORAL CAPSULE 125 MG
- VANFLYTA
- VENCLEXTA ORAL TABLET 10 MG, 100 MG, 50 MG
- VENCLEXTA STARTING PACK
- VERZENIO
- VITRAKVI ORAL CAPSULE 100 MG, 25 MG
- VITRAKVI ORAL SOLUTION
- VIZIMPRO
- VONJO
- VORANIGO
- WELIREG
- XALKORI ORAL CAPSULE

Formulary ID 26323

Last Updated: 10/15/2025

- XALKORI ORAL CAPSULE SPRINKLE 150 MG, 20 MG, 50 MG
- XOSPATA
- XPOVIO (100 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 50 MG
- XPOVIO (40 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 10 MG, 40 MG
- XPOVIO (40 MG TWICE WEEKLY) ORAL TABLET THERAPY PACK 40 MG
- XPOVIO (60 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 60 MG
- XPOVIO (60 MG TWICE WEEKLY)
- XPOVIO (80 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 40 MG
- XPOVIO (80 MG TWICE WEEKLY)
- XTANDI ORAL CAPSULE
- XTANDI ORAL TABLET 40 MG, 80 MG
- YONSA
- ZEJULA ORAL TABLET
- ZELBORAF
- ZOLINZA
- ZYDELIG
- ZYKADIA ORAL TABLET

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	Prescriber must be an oncologist or specialist for submitted diagnosis.
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

APOMORPHINE

Products Affected

- *apomorphine hcl subcutaneous*

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent use with any 5-HT3 antagonist (e.g., ondansetron, alosetron, granisetron)
Required Medical Information	The member has a documented diagnosis of Parkinson's Disease.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a neurologist
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	Parkinson's disease - Initial: (1) tried and failed at least one other treatment for off episodes such as long-acting levodopa formulations or adjunct non-dopaminergic treatment (e.g., amantadine) AND (2) currently receiving carbidopa/levodopa AND (3) experiencing off episodes (i.e. difficulty starting movements, muscle stiffness, and slow movement). Continuation of therapy: patient has positive clinical response to treatment.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

AQNEURSA

Products Affected

- AQNEURSA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	Specialist for submitted diagnosis.
Coverage Duration	New starts will be authorized for 6 months. Cont of therapy or reauth until end of contract year.
Other Criteria	For new starts: 1) The member has a documented diagnosis of Niemann-Pick disease type C (NPC) AND 2) Documentation of genetic testing identifying disease-causing alleles in NPC1 or NPC2 AND 3) Documentation of disease-related neurological symptoms (e.g., developmental delay/regression, ataxia, cataplexy, seizures, motor-function decline, tremors, dysphagia) For reauthorization: Documentation that member has had positive response to therapy (e.g., stabilization in neurological status, decrease in functional Scale for Assessment and Rating of Ataxia [fSARA] score).
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

ARCALYST

Products Affected

- ARCALYST

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with specialist for submitted diagnosis.
Coverage Duration	CAPS-3 mos initial, 1 yr cont. DIRA-6 mos initial, 1 yr cont. Pericard-3 mos initial, 1 yr cont
Other Criteria	Cryopyrin associated periodic syndrome (CAPs) - Initial: patient has diagnosis of CAPs. Continuation of therapy: patient has positive clinical response to treatment. Deficiency of interleukin-1 receptor antagonist (DIRA) - Initial: (1) patient weighs at least 10kg AND (2) genetic test confirms a mutation in the IL1RN gene and the patient has demonstrated a clinical benefit with anakinra subcutaneous injection. Continuation of therapy: patient has positive clinical response to treatment. Gout, flare prevention - Initial: (1) patient has had at least 2 gout flares within the past year AND (2) patient has tried, failed or has contraindication to maximum tolerated doses of non-steroidal inflammatory drug (NSAID) and colchicine AND (3) concurrently using urate-lowering therapy (i.e. allopurinol). Continuation of therapy: (1) patient has positive clinical response to treatment and (2) concurrently using urate-lowering therapy. Pericarditis - Initial: patient has recurrent pericarditis AND requires treatment for current episode. Continuation of therapy: patient has positive clinical response to treatment.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Formulary ID 26323

Last Updated: 10/15/2025

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

ARIKAYCE

Products Affected

- ARIKAYCE

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Mycobacterium avium complex (MAC): (1) Documented diagnosis of MAC lung disease as verified by failure to achieve at least 2 negative sputum cultures following 6 consecutive months of a combination antibacterial drug regimen AND (2) Provider attestation that medication is being used as part of a combination antibacterial drug regimen.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a pulmonologist or an infectious disease specialist
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

ARISTADA

Products Affected

- ARISTADA INITIO 441 MG/1.6ML, 662 MG/2.4ML, 882
- ARISTADA INTRAMUSCULAR MG/3.2ML
- PREFILLED SYRINGE 1064 MG/3.9ML,

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	The member has a documented history of receiving oral aripiprazole without any clinically significant side effects.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	Trial and failure of, contraindication, or medical reason for not using at least two of the following: Abilify Maintena, Abilify Asimtufii, Risperidone Microsphere, Invega Sustenna, Invega Trinza, and Invega Hafyera.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

AUVELITY

Products Affected

- AUVELITY

PA Criteria	Criteria Details
Exclusion Criteria	Seizure disorder.
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	Initial: (1) trial of, contraindication to, or medical reason for not using to two generic antidepressants OR (2) patient has suicidal ideation and provider does not recommend use of other antidepressants.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

AZTREONAM LYSINE

Products Affected

- CAYSTON

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a pulmonologist, infectious diseases specialist, or other provider specializing in cystic fibrosis.
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	Patient has Pseudomonas aeruginosa in culture of the airway (i.e. bronchoalveolar lavage culture, oropharyngeal culture, sputum culture).
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

BENLYSTA

Products Affected

- BENLYSTA SUBCUTANEOUS

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with specialist for submitted diagnosis.
Coverage Duration	New starts will be authorized for 6 months. Cont of therapy or reauth until end of contract year.
Other Criteria	Lupus nephritis - Initial: (1) patient has a diagnosis of lupus nephritis confirmed on biopsy (i.e. World Health Organization class III, IV, or V lupus nephritis) AND (2) the medication is being used concurrently with an immunosuppressive regimen (i.e. azathioprine, methotrexate, mycophenolate mofetil and/or a systemic corticosteroid). Continuation of therapy: (1) medication is being used concurrently with an immunosuppressive regimen (i.e. azathioprine, methotrexate, mycophenolate mofetil and/or a systemic corticosteroid) AND (2) patient has positive clinical response to treatment. Systemic lupus erythematosus (SLE) - Initial: (1) patient has autoantibody-positive SLE (defined as positive for antinuclear antibodies [ANA] and/or antidouble-stranded DNA antibody [anti-dsDNA]) AND (2) the medication is being used concurrently with at least one other standard therapy (i.e., antimalarials [e.g., hydroxychloroquine], a systemic corticosteroid [e.g., prednisone], and/or other immunosuppressants [e.g., azathioprine, mycophenolate mofetil, methotrexate]) unless the patient is determined to be intolerant due to a significant toxicity, as determined by a healthcare provider. Continuation of therapy: (1) the medication is being used concurrently with at least one other standard therapy (defined above) unless the patient is determined to be intolerant due to a significant toxicity AND (2) patient has positive clinical response to treatment.

PA Criteria	Criteria Details
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

BESREMI

Products Affected

- BESREMI

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off-Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	No

BOSENTAN

Products Affected

- bosentan oral tablet*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Pulmonary arterial hypertension (PAH) (World Health Organization [WHO] Group - Initial: [Note: documentation required] (1) PAH was confirmed by right heart catheterization AND (2) pretreatment mean pulmonary arterial pressure is greater than 20 mmHg AND (3) pretreatment pulmonary capillary wedge pressure is less than or equal to 15 mmHg, AND (4) pretreatment pulmonary vascular resistance is greater than or equal to 3 Wood units. Continuation of therapy: patient has positive clinical response to treatment.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a cardiologist or pulmonologist.
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

CABLIVI

Products Affected

- CABLIVI

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Documented diagnosis of medically accepted indication and date of last plasma exchange.
Age Restrictions	18 years of age or older.
Prescriber Restrictions	Prescribed by or in consultation with a hematologist.
Coverage Duration	Request will be authorized until 2 months after the date of the last plasma exchange.
Other Criteria	Cablivi is being used in combination with plasma exchange and immunosuppressive therapy (i.e. cyclosporine, cyclophosphamide, mycophenolate mofetil, systemic corticosteroids).
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

CAMZYOS

Products Affected

- CAMZYOS

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Initial: [Note: documentation required] (1) diagnosis of obstructive hypertrophic cardiomyopathy (HCM) AND (2) patient has New York Heart Association (NYHA) Class II or III symptoms AND (3) patient has a left ventricular ejection fraction of greater than or equal to 55% AND (4) patient has valsalva left ventricular outflow tract (LVOT) peak gradient which is greater than or equal to 50 mmHg at rest or with provocation AND (5) patient has tried and failed, or has contraindication or intolerance to both of the following at max tolerated dose: non-vasodilating beta blocker (i.e. bisoprolol, propranolol) AND calcium channel blocker (i.e. verapamil, diltiazem). Continuation of therapy: (1) patient must have a LVEF greater than or equal to 50% AND (2) patient has had clinically significant improvement of symptoms AND (3) prescriber attestation patient has not and will not receive septal reduction therapy (SRT) while on mavacamten therapy.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a cardiologist.
Coverage Duration	Initial: 6 months. Continuation of therapy: end of contract year.
Other Criteria	For all new starts, ALL of the following must be provided: 1) Diagnosis of symptomatic New York Heart Association (NYHA) class II or III obstructive hypertrophic cardiomyopathy (oHCM) AND 2) Patient has a left ventricular ejection fraction (LVEF) greater than or equal to 55% AND 3) Assessment of Valsalva left ventricular outflow tract (LVOT) gradient AND 4) Trial of, medical reason for not using or contraindication to BOTH of the following: Beta blockers (i.e. metoprolol, propranolol, atenolol) AND Non-dihydropyridine calcium channel blockers (i.e. verapamil, diltiazem) AND 5) Prescriber attests that patient is not using moderate to strong CYP2C19 or CYP3A4 inhibitors or inducers. For continuation of therapy or reauthorization, all of the following must be provided: 1)

PA Criteria	Criteria Details
	Documentation of clinical benefit as evidenced by an improvement from baseline in oHCM symptoms (i.e., improvement in fatigue, chest pain, shortness of breath, LVOT, peak oxygen consumption, etc.) OR improvement or no worsening of NYHA functional class AND 2) Member must also have a left ventricular ejection fraction (LVEF) greater than or equal to 50%.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

CARGLUMIC ACID

Products Affected

- carglumic acid oral tablet soluble*

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off-Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	No

CASPOFUNGIN

Products Affected

- *caspofungin acetate*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	Documentation of a consultation with an infectious disease specialist.
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

CEPROTIN

Products Affected

- CEPROTIN

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Documented diagnosis of congenital protein C deficiency as confirmed by lab values indicating low protein C activity.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a hemotologist or specialist in genetic disorders.
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

CERDELGA

Products Affected

- CERDELGA

PA Criteria	Criteria Details
Exclusion Criteria	Patients with undetermined CYP2D6 metabolizer status.
Required Medical Information	Type 1 Gaucher Disease (GD1) - Initial: [Note: documentation required] (1) diagnosis confirmed by an enzyme assay demonstrating deficiency of beta-glucocerebrosidase enzyme activity OR genetic testing AND (2) patient's CYP2D6 metabolizer status has been confirmed by FDA cleared test AND (3) patient is CYP2D6 extensive metabolizer, intermediate metabolizer, or a poor metabolizer. Continuation of therapy: documentation has been provided that patient has obtained clinical benefit from medication (i.e. increased platelet count, improvement in anemia, PFTs, improvement in radiographic scans, improved quality of life).
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a specialist in treatment of Gaucher's disease.
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

CHENODAL

Products Affected

- CHENODAL

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	The member has a documented diagnosis of radiolucent gallstones.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	Trial and failure of, contraindication, or medical reason for not using ursodiol.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

CHOLBAM

Products Affected

- CHOLBAM

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent use with Chenodal.
Required Medical Information	Bile acid synthesis defect due to single enzyme defect - Initial: documented diagnosis based on an abnormal urinary bile acid as confirmed by Fast Atom Bombardment ionization - Mass Spectrometry (FAB-MS) analysis or molecular genetic testing consistent with the diagnosis. Continuation of therapy: (1) responded to initial Cholbam therapy with an improvement in LFTs AND (2) does not have complete biliary obstruction. Bile acid synthesis disorders due to peroxisomal disorders, including Zellweger spectrum disorders - Initial: (1) documented peroxisomal disorders with an abnormal urinary bile acid analysis by FAB-MS or molecular genetic testing consistent with the diagnosis AND (2) has liver disease, steatorrhea, or complications from decreased fat soluble vitamin absorption (i.e. rickets). Continuation of therapy: (1) responded to initial Cholbam therapy as per the prescriber (i.e. improvements in liver enzymes, improvement in steatorrhea) AND (2) does not have complete biliary obstruction.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with hepatologist, gastroenterologist, metabolic specialist.
Coverage Duration	Initial: 3 months. Continuation of therapy: end of contract year.
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

Formulary ID 26323

Last Updated: 10/15/2025

CIBINQO

Products Affected

- CIBINQO

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent use with a biologic, targeted disease modifying antirheumatic drug (DMARD), anti-interleukin monoclonal antibody, janus kinase inhibitors, immunomodulators, with other potent immunosuppressants.
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	Initial therapy only: prescribed by or in consultation with an allergist, dermatologist, or immunologist.
Coverage Duration	Initial: 3 months. Continuation of therapy: end of calendar year
Other Criteria	Atopic Dermatitis - Initial: (1) patient has had a 3-month trial of at least one traditional systemic therapy (i.e. azathioprine, cyclosporine, and mycophenolate mofetil) OR (2) patient has tried at least one traditional systemic therapy but was unable to tolerate a 3-month trial. Note: A patient who has already tried Dupixent (dupilumab subcutaneous injection) or Adbry (tralokinumab-ldrm subcutaneous injection) is not required to step back and try a traditional systemic agent for atopic dermatitis. Continuation of therapy: (1) patient has been receiving Cibirno for at least 90 days AND (2) patient experienced a beneficial clinical response, defined as improvement from baseline (prior to initiating Cibirno) in at least one of the following: (i) estimated body surface area affected, (ii) erythema, (iii) excoriations, (iv) induration/papulation/edema, (v) lichenification, and/or (vi) decreased requirement for other topical or systemic therapies for atopic dermatitis AND (3) compared with baseline (prior to receiving Cibirno), patient experienced an improvement in at least one symptom (i.e. decreased itching).
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

PA Criteria	Criteria Details
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

CIMZIA

Products Affected

- CIMZIA (2 SYRINGE)
- CIMZIA SUBCUTANEOUS KIT 2 X 200 MG
- CIMZIA-STARTER

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with specialist for submitted diagnosis.
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	For ankylosing spondylitis (AS): Trial of, medical reason for not using, or contraindication to 2 of the following therapies: Enbrel, Cosentyx, an adalimumab product, or Xeljanz. For Crohn's Disease (CD): Trial of, medical reason for not using, or contraindication to 2 of the following therapies: an adalimumab product, or an ustekinumab product. For non-radiographic axial spondylarthritis: approve. For psoriasis (PS): Trial of, medical reason for not using, or contraindication to 2 of the following therapies: Tremfya, an ustekinumab product, Enbrel, or an adalimumab product. For Psoriatic arthritis (PsA): Trial of, medical reason for not using, or contraindication to 2 of the following therapies: an ustekinumab product, Tremfya, Xeljanz, Enbrel, Cosentyx or an adalimumab product. For Rheumatoid arthritis (RA): Trial of, medical reason for not using, or contraindication to 2 of the following: Enbrel, an adalimumab product, or Xeljanz. Polyarticular juvenile idiopathic arthritis (pJIA) - Initial: trial of, medical reason for not using, or contraindication to 2 of the following: Enbrel, an adalimumab product, or Xeljanz. AS/CD/PS/PsA/RA/pJIA Continuation of therapy: patient has positive clinical response to treatment.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

PA Criteria	Criteria Details
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

CORLANOR

Products Affected

- CORLANOR ORAL SOLUTION
- *ivabradine hcl oral tablet 5 mg, 7.5 mg*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	New starts for chronic heart failure must have all of the following: 1) LVEF of 35% or less 2) Sinus rhythm and have resting heart rate greater than or equal to 70 bpm. For pediatric patients with heart failure due to dilated cardiomyopathy: approve
Age Restrictions	N/A
Prescriber Restrictions	Prescriber must be a cardiologist.
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	Trial of, contraindication to, or medical reason for not receiving a beta blocker.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

CORTROPHIN

Products Affected

- CORTROPHIN
- CORTROPHIN GEL

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	New starts for MS exacerbation, rheumatic disorders, collagen diseases, dermatologic diseases, serum sickness, edematous state (e.g. nephrotic syndrome without uremia), and respiratory diseases: trial of, contraindication to, or medical reason for not using oral corticosteroids. New starts for ophthalmic disease: trial of, contraindication to, or medical reason for not using oral or ophthalmic corticosteroids. Continuation of therapy or reauthorization for MS exacerbation: documentation of symptom improvement and current use of a multiple sclerosis disease modifying agent for maintenance therapy. Continuation of therapy or reauthorization for all other conditions: documented evidence of response to treatment and symptom improvement.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with specialist for submitted diagnosis.
Coverage Duration	MS exacerbation: 1 month. Other conditions: new start for 3 months and reauth end of contract year.
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

COSENTYX

Products Affected

- COSENTYX (300 MG DOSE)
- COSENTYX INTRAVENOUS
- COSENTYX SENSOREADY (300 MG)
- COSENTYX SENSOREADY PEN
- COSENTYX SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 150 MG/ML, 75 MG/0.5ML
- COSENTYX UNOREADY

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	Documented diagnosis of ankylosing spondylitis, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, enthesitis-related arthritis, rheumatoid arthritis or hidradenitis suppurativa.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

CRESEMBA

Products Affected

- CRESEMBA ORAL

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Documented diagnosis of medically accepted indication.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an infectious disease specialist or oncologist
Coverage Duration	Request will be authorized for 3 months.
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

CRYSVITA

Products Affected

- CRYSVITA

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent use with oral phosphate or active vitamin D analogs. Use in patients with severe renal impairment or end stage renal disease (ESRD).
Required Medical Information	X-linked hypophosphatemia (XLH): Documented diagnosis of XLH as confirmed by one of the following: 1) elevated serum fibroblast growth factor-23 (FGF23) level OR 2) genetic testing. Tumor-induced osteomalacia (TIO): 1) Documented diagnosis of FGF23-related hypophosphatemia in TIO associated with phosphaturic mesenchymal tumors AND 2) provider attestation that disease cannot be curatively resected or localized.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a geneticist, nephrologist or endocrinologist.
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	Documentation of low serum phosphate concentration.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

CYSTAGON

Products Affected

- CYSTAGON

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent use with Procysbi.
Required Medical Information	For nephropathic cystinosis: documented diagnosis confirmed with at least one of the following: (1) the presence of increased cystine concentration in leukocytes, OR (2) genetic testing, OR (3) demonstration of corneal cystine crystals by slit lamp examination.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a metabolic disease specialist or nephrologist.
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

CYSTARAN

Products Affected

- CYSTARAN

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	For cystinosis: (1) documented diagnosis confirmed with at least one of the following: (i) the presence of increased cystine concentration in leukocytes, OR (ii) genetic testing, OR (iii) demonstration of corneal cystine crystals by slit lamp examination. AND (2) the patient has corneal cystine crystal accumulation.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an ophthalmologist or metabolic disease specialist.
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

DALFAMPRIDINE ER

Products Affected

- *dalfampridine er*

PA Criteria	Criteria Details
Exclusion Criteria	History of seizure or moderate/severe renal impairment (CrCl less than or equal to 50 mL/min).
Required Medical Information	For multiple sclerosis - Initial: patient demonstrates sustained walking impairment. Continuation of therapy: (1) patient must have experienced an improvement in walking speed OR (2) other objective measure of walking ability (i.e. MS walking scale, timed 25-foot walk) since starting the requested drug.
Age Restrictions	18 years of age or older.
Prescriber Restrictions	Prescribed by or in consultation with a neurologist.
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

DEFERASIROX

Products Affected

- *deferasirox*
- *deferasirox granules*

PA Criteria	Criteria Details
Exclusion Criteria	Creatinine clearance less than 40 mL/min or platelet counts less than 50,000/mm ³ .
Required Medical Information	Serum ferritin level.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a hematologist.
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	Transfusion-related chronic iron overload - Initial: (1) patient is receiving blood transfusions at regular intervals for various conditions (i.e. chronic anemia, myelodysplastic syndrome, sickle cell disease, thalassemia syndromes) AND (2) prior to starting therapy, the serum ferritin level is greater than 1,000 mcg/L. Non-transfusion-dependent thalassemia syndromes chronic iron overload - Initial: approve if prior to starting therapy the serum ferritin level is greater than 300 mcg/L. Continuation of therapy: patient has positive clinical response to treatment.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

DEFERIPRONE

Products Affected

- *deferiprone*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Serum ferritin level.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a hematologist.
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	Iron overload, chronic-transfusion related due to thalassemia syndrome or related to sickle cell disease or other anemias - Initial: approve. Continuation of therapy: patient has positive clinical response to treatment.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

DEFLAZACORT

Products Affected

- *deflazacort*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	1) Member has a documented diagnosis of Duchenne Muscular Dystrophy as evidenced by one of the following: a) documented mutation of dystrophin gene OR b) muscle biopsy indicating absence of the dystrophin protein AND 2) Patient has trial and failure with, contraindication to or medical reason for not taking prednisone.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a neurologist or specialist for submitted diagnosis.
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

DIACOMIT

Products Affected

- DIACOMIT ORAL CAPSULE 250 MG, 500 MG
- DIACOMIT ORAL PACKET 250 MG, 500 MG

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	Initial therapy only: 6 months of age or older.
Prescriber Restrictions	Initial therapy only: prescribed by or in consultation with a neurologist.
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	Dravet Syndrome -Initial: patient is concomitantly receiving clobazam or is unable to take clobazam due to adverse events. Continuation of therapy: patient has positive clinical response to treatment.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

DIHYDROERGOTAMINE NASAL

Products Affected

- *dihydroergotamine mesylate nasal*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	For new starts: Member has a diagnosis of migraine headaches with or without aura. Prescriber attestation that it will be used for the acute treatment of migraine. For continuation of therapy or reauthorization: Documentation or provider attestation of positive clinical response (e.g., improvement in pain, photophobia, phonophobia).
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	New starts will be authorized for 6 months. Cont of therapy or reauth until end of contract year.
Other Criteria	Trial of, contraindication to, or medical reason (e.g. intolerance or hypersensitivity) for not using a triptan (e.g., rizatriptan, sumatriptan).
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

DOPTELET

Products Affected

- DOPTELET

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off-Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

DOXEPIN CREAM

Products Affected

- *doxepin hcl external*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Request will be authorized for 14 days.
Other Criteria	(1) Trial of, contraindication to, or medical reason (i.e. treatment on axilla, face or groin) for not using a topical corticosteroid [potency of medium or higher] OR (2) topical calcineurin inhibitor.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

DROXIDOPA

Products Affected

- *droxidopa oral capsule 100 mg, 200 mg, 300 mg*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Neurogenic orthostatic hypotension (NOH): patient meets the following requirements (1) diagnosed with symptomatic NOH due to primary autonomic failure (Multiple system atrophy, Parkinson's disease, and pure autonomic failure), dopamine beta-hydroxylase deficiency, or non-diabetic autonomic neuropathy, AND (2) patient has tried and failed midodrine.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a cardiologist or a neurologist.
Coverage Duration	Request will be authorized for 3 months.
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

DUPIXENT

Products Affected

- DUPIXENT SUBCUTANEOUS SOLUTION AUTO-INJECTOR 200 MG/1.14ML, 300 MG/2ML
- DUPIXENT SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 200 MG/1.14ML, 300 MG/2ML

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off-Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

EGRIFTA

Products Affected

- EGRIFTA SV
- EGRIFTA WR

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Documentation of active antiretroviral therapy for at least 8 weeks.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

EMGALITY

Products Affected

- EMGALITY
- EMGALITY (300 MG DOSE)

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off-Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

EMSAM

Products Affected

- EMSAM

PA Criteria	Criteria Details
Exclusion Criteria	Concomitant use with SSRIs, SNRIs, clomipramine and imipramine, meperidine, tramadol, methadone, pentazocine, and propoxyphene, and the antitussive agent dextromethorphan or carbamazepine
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	Initial: (1) trial of, contraindication to, or medical reason for not using two generic antidepressants OR (2) patient is unable to swallow oral formulations.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

ENBREL

Products Affected

- ENBREL MINI
- ENBREL SUBCUTANEOUS SOLUTION 25 MG/0.5ML
- ENBREL SUBCUTANEOUS SOLUTION PREFILLED SYRINGE
- ENBREL SURECLICK SUBCUTANEOUS SOLUTION AUTO-INJECTOR

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off-Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

ENDARI

Products Affected

- *l-glutamine oral packet*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Documentation that two or more painful sickle cell crises have occurred in the past 12 months.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a hematologist, oncologist, or another provider specializing in sickle cell disease.
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	Trial of, contraindication to, or medical reason for not using hydroxyurea for at least three months.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

ENTYVIO

Products Affected

- ENTYVIO PEN

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off-Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

EPIDIOLEX

Products Affected

- EPIDIOLEX

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	1 year of age or older.
Prescriber Restrictions	Initial therapy only; prescribed by or in consultation with a neurologist.
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	Dravet Syndrome -Initial: (1) patient has tried or is currently taking at least 2 other antiseizure medications OR (2) patient has tried or is currently taking clobazam, Diacomit, or Fintepla. Continuation of therapy: patient has positive clinical response to treatment. Lennox Gastaut Syndrome - Initial: patient has tried or is currently taking at least 2 other antiseizure medications. Continuation of therapy: patient has positive clinical response to treatment. Tuberous Sclerosis Complex - Initial: patient has tried or is currently taking at least 2 other antiseizure medications. Continuation of therapy: patient has positive clinical response to treatment.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

EPRONTIA

Products Affected

- *topiramate oral solution*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	Epilepsy: 2 years of age or older. Migraine: 12 years of age or older.
Prescriber Restrictions	N/A
Coverage Duration	The request will be authorized until the end of the contract year.
Other Criteria	Initial: documented trial of, contraindication to, or medical reason for not using topiramate. Continuation of therapy: patient has positive clinical response to treatment.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

ERYTHROPOIETIN STIMULATING AGENTS

Products Affected

- ARANESP (ALBUMIN FREE) INJECTION SOLUTION 100 MCG/ML, 200 MCG/ML, 25 MCG/ML, 40 MCG/ML, 60 MCG/ML
- ARANESP (ALBUMIN FREE) INJECTION SOLUTION PREFILLED SYRINGE
- EPOGEN INJECTION SOLUTION 10000 UNIT/ML, 2000 UNIT/ML, 20000 UNIT/ML, 3000 UNIT/ML, 4000 UNIT/ML, 4000 UNIT/ML
- PROCRIT
- RETACRIT INJECTION SOLUTION 10000 UNIT/ML, 10000 UNIT/ML(1ML), 2000 UNIT/ML, 20000 UNIT/ML, 3000 UNIT/ML, 4000 UNIT/ML, 40000 UNIT/ML

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	For new starts for all indications: Hgb within compendia range for treatment of the requested medical condition. For continuation of therapy or re-authorization: Hgb must not exceed 10 g/dL (anemia related to cancer), 11 g/dL (anemia of CKD), 12 g/dL (zidovudine-related anemia in members with HIV and ribavirin-induced anemia), 13 g/dL (elective, noncardiac, nonvascular surgery needing red blood cell allogeneic transfusion reduction).
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Request will be authorized for 6 months.
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

ERZOFRI

Products Affected

- ERZOFRI INTRAMUSCULAR MG/1.5ML, 351 MG/2.25ML, 39
SUSPENSION PREFILLED SYRINGE MG/0.25ML, 78 MG/0.5ML
117 MG/0.75ML, 156 MG/ML, 234

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off-Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

EUCRISA

Products Affected

- EUCRISA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	Prescriber must be a dermatologist, immunologist or an allergist.
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	Trial of, contraindication to, or medical reason for not using topical pimecrolimus. For patients less than 2 years of age: approve.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

EVRYSDI

Products Affected

- EVRYSDI ORAL SOLUTION RECONSTITUTED
- EVRYSDI ORAL TABLET

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off-Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	No

FABHALTA

Products Affected

- FABHALTA

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent use with another complement inhibitor (i.e. Empaveli, Soliris, or Ultomiris).
Required Medical Information	PNH - Initial: patient has documented diagnosis of paroxysmal nocturnal hemoglobinuria (PNH) confirmed by (1) flow cytometry analysis confirming presence of PNH clones AND (2) patient has signs and symptoms of PNH (i.e. anemia, abdominal pain, dyspnea, kidney disease, pulmonary hypertension, hemolysis/hemoglobinuria, etc.). Continuation of therapy: patient has documented positive clinical response to treatment (i.e. decrease in LDH, increased or stabilization of hemoglobin levels, reduction in transfusions, increased reticulocyte count, etc.). Reduction of proteinuria in adults with immunoglobulin A (IgA) nephropathy - Initial: patient has documented diagnosis of IgA nephropathy AND IgA nephropathy at risk of rapid disease progression (i.e. clinical evidence of rapid disease progression generally a urine protein-to-creatinine ratio or UPCR greater or equal to 1.5g/g OR other clinically relevant tests). Continuation of therapy: patient has documented positive clinical response to treatment.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a hematologist, nephrologist or oncologist.
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

Formulary ID 26323

Last Updated: 10/15/2025

FASENRA

Products Affected

- FASENRA PEN
- FASENRA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 10 MG/0.5ML, 30 MG/ML

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Documented diagnosis of medically-accepted indication.
Age Restrictions	N/A
Prescriber Restrictions	Initial therapy only: prescribed by or in consultation with specialist for submitted diagnosis.
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	New starts for severe asthma with an eosinophilic phenotype: 1)Baseline blood eosinophil count greater than or equal to 150 cells per microliter AND 2) symptoms persist with at least 1 exacerbation in the last 12 months requiring additional treatment (e.g. oral systemic steroids) while on a high dose inhaled corticosteroid with an additional controller medication (ie. long-acting B2 agonist). Continuation of therapy or re-authorization for severe asthma with an eosinophilic phenotype: clinical benefit from use of the drug. New starts for eosinophilic granulomatosis with polyangiitis (EGPA)- Initial: patient has a documented history or the presence of an eosinophil count of more than 1000 cells per microliter or a blood eosinophil level of greater than 10 percent AND trial of, contraindication to, or medical reason for not using one of the following medications: cyclophosphamide or methotrexate. Continuation of therapy: patient has a beneficial response to treatment with the requested drug (i.e. a reduction in the frequency of relapses, decrease in the daily oral corticosteroid dose, or no active vasculitis).
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

PA Criteria	Criteria Details
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

FILSPARI

Products Affected

- FILSPARI

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off-Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

FINTEPLA

Products Affected

- FINTEPLA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	2 year of age or older.
Prescriber Restrictions	Initial therapy only; prescribed by or in consultation with a neurologist.
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	Dravet Syndrome - Initial: (1) patient has tried or is currently taking at least 2 other antiseizure medications OR (2) patient has tried or is currently taking clobazam, Diacomit, or Epidiolex. Continuation of therapy: patient has positive clinical response to treatment. Lennox Gastaut Syndrome - Initial: patient has tried or is currently taking at least 2 other antiseizure medications. Continuation of therapy: patient has positive clinical response to treatment.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

FIRDAPSE

Products Affected

- FIRDAPSE

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off-Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	No

FLUCYTOSINE

Products Affected

- *flucytosine oral*

PA Criteria	Criteria Details
Exclusion Criteria	Complete dihydropyrimidine dehydrogenase (DPD) enzyme deficiency
Required Medical Information	Attestation member is taking in combination with amphotericin B.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Request will be authorized for 6 weeks.
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

FULVESTRANT

Products Affected

- fulvestrant intramuscular solution
prefilled syringe*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Documented diagnosis of hormone receptor (HR)-positive advanced or metastatic breast cancer. Patient must have documentation of one of the following: 1) a negative human epidermal growth factor 2 (HER2) biopsy OR 2) disease progression following endocrine therapy (e.g., tamoxifen, toremifene).
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a hematologist or oncologist.
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

GALAFOLD

Products Affected

- GALAFOLD

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent use with Fabrazyme (agalsidase beta).
Required Medical Information	Initial: patient has all of the following confirmed by documentation: (1) diagnosis of Fabry disease AND (2) patient has an amenable galactosidase alpha gene (GLA) variant based on in vitro assay data.
Age Restrictions	N/A
Prescriber Restrictions	Prescriber must be a geneticist, cardiologist, nephrologist or specialist experienced in the treatment of Fabry disease.
Coverage Duration	Request will be authorized to the end of the contract year.
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

GATTEX

Products Affected

- GATTEX

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off-Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

GLP-1 AGONISTS

Products Affected

- *liraglutide*
- OZEMPIC (0.25 OR 0.5 MG/DOSE) SUBCUTANEOUS SOLUTION PEN-INJECTOR 2 MG/3ML
- OZEMPIC (1 MG/DOSE) SUBCUTANEOUS SOLUTION PEN-INJECTOR 4 MG/3ML
- OZEMPIC (2 MG/DOSE)
- RYBELSUS

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off-Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

GNRH AGONISTS

Products Affected

- ELIGARD
- FIRMAGON (240 MG DOSE)
- FIRMAGON SUBCUTANEOUS SOLUTION RECONSTITUTED 80 MG
- *leuprolide acetate (3 month)*
- *leuprolide acetate injection*
- LUPRON DEPOT (1-MONTH)
- LUPRON DEPOT (3-MONTH)
- LUPRON DEPOT (4-MONTH)
- LUPRON DEPOT (6-MONTH)
- LUTRATE DEPOT
- TRELSTAR MIXJECT

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with specialist for submitted diagnosis.
Coverage Duration	Fibroids and endometriosis: 6 months. All other indications: end of contract year.
Other Criteria	If the medication request is for the treatment of prostate cancer and if the request is for any other GnRH agonist other than Eligard or leuprolide, the patient must have a documented trial of, contraindication to, or medical reason for not using Eligard or leuprolide to treat their prostate cancer. For uterine fibroids: (1) patient has anemia (i.e. hematocrit less than or equal to 30 percent and/or hemoglobin less than or equal to 10 g/dL) OR (2) the requested medication will be used prior to surgery for uterine fibroids.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Formulary ID 26323

Last Updated: 10/15/2025

GOCOVRI

Products Affected

- GOCOVRI ORAL CAPSULE
EXTENDED RELEASE 24 HOUR 137
MG, 68.5 MG

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with neurologist.
Coverage Duration	Initial: 3 months. Continuation of therapy: end of contract year.
Other Criteria	Initial: (1) patient has been diagnosed with Parkinson's disease AND (2) patient is experiencing dyskinesia OR 'off' episodes AND (3) patient has trial of generic amantadine OR contraindication or medical reason for not using generic amantadine. Continuation of therapy: patient has positive clinical response to treatment (i.e. improvement in levodopa-induced dyskinesia).
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

GROWTH HORMONES

Products Affected

- GENOTROPIN MINIQUEL SUBCUTANEOUS PREFILLED SYRINGE
- GENOTROPIN SUBCUTANEOUS CARTRIDGE
- NGENLA
- OMNITROPE SUBCUTANEOUS SOLUTION CARTRIDGE
- OMNITROPE SUBCUTANEOUS SOLUTION RECONSTITUTED
- SKYTROFA SUBCUTANEOUS CARTRIDGE 11 MG, 13.3 MG, 3 MG, 3.6 MG, 4.3 MG, 5.2 MG, 6.3 MG, 7.6 MG, 9.1 MG

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off-Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	No

HEREDITARY ANGIOEDEMA AGENTS

Products Affected

- BERINERT
- CINRYZE
- HAEGARDA SUBCUTANEOUS SOLUTION RECONSTITUTED 2000 UNIT, 3000 UNIT
- ORLADEYO

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an allergist, hematologist, immunologist, rheumatologist, or a provider that specializes in the treatment of HAE or related disorders.
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	Prophylaxis of hereditary angioedema (HAE) - Initial: diagnosis of HAE confirmed by (1) C1 inhibitor (C1-INH) antigenic level below the lower limit of normal OR (2) C1-INH functional level below the lower limit of normal OR (3) if patient has HAE with normal C1-INH levels they must have (i) recurring angioedema attacks that are refractory to high-dose antihistamines with confirmed family history of angioedema OR (ii) confirmed presence of a Factor XII (FXII), angiopoietin-1, or plasminogen gene mutation. Continuation of therapy: patient has positive clinical response to treatment. Treatment of acute HAE attacks - Initial: diagnosis of HAE confirmed by (1) C1 inhibitor (C1-INH) antigenic level below the lower limit of normal OR (2) C1-INH functional level below the lower limit of normal OR (3) if patient has HAE with normal C1-INH levels they must have (i) recurring angioedema attacks that are refractory to high-dose antihistamines with confirmed family history of angioedema OR (ii) confirmed presence of a Factor XII (FXII), angiopoietin-1, or plasminogen gene mutation AND (4) patient has tried or has medical reason for not using icatibant. Continuation of therapy: patient has positive clinical response to treatment.

PA Criteria	Criteria Details
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

HIGH DOSE OPIOID

Products Affected

- *fentanyl transdermal patch 72 hour 100 mcg/hr*
- *methadone hcl oral tablet 10 mg*
- *morphine sulfate er oral tablet extended release 100 mg, 200 mg*

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off-Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

HIGH RISK MEDICATION

Products Affected

- *amitriptyline hcl oral*
- *amoxapine*
- *benztropine mesylate oral*
- *clomipramine hcl oral*
- *cyproheptadine hcl oral*
- *diphenoxylate-atropine oral liquid*
- *diphenoxylate-atropine oral tablet 2.5-0.025 mg*
- *dipyridamole oral*
- *doxepin hcl oral capsule*
- *doxepin hcl oral concentrate*
- *ergotamine-caffeine*
- *hydroxyzine hcl oral syrup*
- *hydroxyzine hcl oral tablet*
- *hydroxyzine pamoate oral*
- *imipramine hcl oral*
- *imipramine pamoate oral capsule 100 mg, 125 mg, 150 mg, 75 mg*
- *nifedipine oral*
- *promethazine-phenylephrine*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	For patients 65 years old and older the prescriber has documented: the benefits of treatment with the drug outweigh the potential risks
Age Restrictions	Prior authorization only applies to members 65 years old or older.
Prescriber Restrictions	N/A
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

HIGH RISK MEDICATION - PROTECTED CLASS DRUGS

Products Affected

- *phenobarbital oral elixir 20 mg/5ml*
- *phenobarbital oral tablet*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	For patients 65 years old and older the prescriber has documented: the benefits of treatment with the drug outweigh the potential risks
Age Restrictions	Prior authorization only applies to members 65 years old or older.
Prescriber Restrictions	N/A
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

HIGH RISK MEDICATION, BUTALBITAL

Products Affected

- BAC (BUTALBITAL-ACETAMIN-CAFF)
- *butalbital-acetaminophen oral tablet 50-325 mg*
- *butalbital-apap-caff-cod oral capsule 50-325-40-30 mg*
- *butalbital-apap-caffeine oral capsule 50-325-40 mg*
- *butalbital-apap-caffeine oral solution*
- *butalbital-apap-caffeine oral tablet 50-325-40 mg*
- *butalbital-asa-caff-codeine*
- *butalbital-aspirin-caffeine oral capsule*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	For patients 65 years old and older the prescriber has documented: the benefits of treatment with the drug outweigh the potential risks
Age Restrictions	Prior authorization only applies to members 65 years old or older.
Prescriber Restrictions	N/A
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	Trial of, contraindication to, or medical reason for not using an oral NSAID.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

HIGH RISK MEDICATION, MEGESTROL

Products Affected

- *megestrol acetate oral suspension 40 mg/ml, 400 mg/10ml, 625 mg/5ml*
- *megestrol acetate oral tablet*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	For patients 65 years old and older the prescriber has documented: the benefits of treatment with the drug outweigh the potential risks identified for people 65 years old and older.
Age Restrictions	Prior authorization only applies to members 65 years old or older.
Prescriber Restrictions	N/A
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

HIGH RISK MEDICATION, SHORT TERM MUSCLE RELAXANT

Products Affected

- *carisoprodol oral*
- *chlorzoxazone oral tablet 500 mg*
- *cyclobenzaprine hcl oral tablet 10 mg, 5 mg*
- *metaxalone oral tablet 800 mg*
- *methocarbamol oral tablet 500 mg, 750 mg*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	For patients 65 years old and older the prescriber has documented: (1) the benefits of treatment with the drug outweigh the potential risks identified for people 65 years old and older AND (2) if the patient is taking one or more additional anticholinergic medication (i.e. amitriptyline, cyclobenzaprine, dicyclomine, meclizine, oxybutynin, paroxetine, etc.) with the requested drug, the prescriber has determined that taking multiple anticholinergic medications is medically necessary.
Age Restrictions	Prior authorization only applies to members 65 years old or older.
Prescriber Restrictions	N/A
Coverage Duration	New starts will be authorized for 30 days. Continuation of therapy or reauth will be for 90 days.
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

HIGH RISK MEDICATION, SLEEP AGENTS

Products Affected

- *eszopiclone*
- *temazepam*
- *zaleplon*
- *zolpidem tartrate er*
- *zolpidem tartrate oral tablet*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	For patients 65 years old and older the prescriber has documented: the benefits of treatment with the drug outweigh the potential risks identified for people 65 years old and older. For zolpidem immediate release 10mg and zolpidem ER: trial of or medical reason for not using zolpidem immediate release 5mg.
Age Restrictions	Prior authorization only applies to members 65 years old or older.
Prescriber Restrictions	N/A
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

HYFTOR

Products Affected

- HYFTOR

PA Criteria	Criteria Details
Exclusion Criteria	Concurrently receiving systemic mTOR inhibitor therapy such as everolimus.
Required Medical Information	Facial angiofibroma - Initial: patient must meet all of the following criteria: (1) documented diagnosis of tuberous sclerosis complex (TSC) AND (2) experiencing three or more facial angiofibromas. Continuation of therapy: patient has positive clinical response to treatment (i.e. improvement in size of redness of facial angiofibroma).
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with specialist for submitted diagnosis.
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

ICATIBANT

Products Affected

- *icatibant acetate subcutaneous solution
prefilled syringe*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an allergist, immunologist, rheumatologist. Or provider that specializes in the treatment of HAE or related disorders.
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	For acute angioedema attacks due to hereditary angioedema (HAE) patient meets either of the following - Initial: (1) patient has HAE with C1 inhibitor deficiency or dysfunction confirmed by laboratory testing OR (2) the patient has HAE with normal C1 inhibitor confirmed by laboratory testing and at least one of the following: i) the patient tested positive for an F12, angiopoietin-1, heparan sulfate glucosamine 3-O sulfotransferase 6 (HS3ST6), myoferlin (MYOF) gene mutation, or plasminogen, kininogen-1 (KNG1) OR ii) the patient has a family history of angioedema and the angioedema was refractory to a trial of high-dose antihistamine therapy for at least one month.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Formulary ID 26323
Last Updated: 10/15/2025

ILARIS

Products Affected

- ILARIS SUBCUTANEOUS SOLUTION

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Documentation was submitted indicating that the member was evaluated for active or latent TB infection (i.e. tuberculin skin test)
Age Restrictions	N/A
Prescriber Restrictions	Specialist for submitted diagnosis.
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	For sJIA: approve. For gout, both of the following are required: 1) Documented trial of, contraindication to, or medical reason for not using nonsteroidal anti-inflammatory drugs and colchicine AND 2) Documented medical reason that repeated corticosteroid use is not appropriate.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

ILUMYA

Products Affected

- ILUMYA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	Specialist for submitted diagnosis.
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	Initial: (1) patient has psoriasis affecting 3% or greater surface area involvement OR (2) psoriasis in sensitive areas such as face, groin, palms, soles of feet or scalp AND (2) patient has history of failure or medical reason for not using at least one conventional topical therapy (i.e. calcineurin inhibitors, corticosteroids, tazarotene or vitamin D analogs) AND (3) patient has history of failure or medical reason for not using at least one of the following products: an adalimumab product, Enbrel, Tremfya or an ustekinumab product. Continuation of therapy: patient has positive clinical response to therapy.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

IMBRUVICA

Products Affected

- IMBRUVICA ORAL CAPSULE 140 MG, 70 MG
- IMBRUVICA ORAL TABLET 140 MG, 280 MG, 420 MG
- IMBRUVICA ORAL SUSPENSION

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	Prescriber must be an oncologist or specialist for submitted diagnosis.
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	Graft-versus-host disease (GVHD) - Initial: trial of, contraindication to, or medical reason for not using a systemic corticosteroid or other conventional systemic treatment for GVHD (i.e. corticosteroids [methylprednisolone, prednisone], imatinib, low-dose methotrexate, sirolimus, mycophenolate mofetil, etc.). Continuation of therapy: documentation of clinical benefit from use of the drug (i.e. symptom improvement, reduction in corticosteroid dose). For all other indications, approve.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

IMPAVIDO

Products Affected

- IMPAVIDO

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Documentation of diagnosis with one of the following: (a) Visceral leishmaniasis due to <i>Leishmania donovani</i> , (b) Cutaneous leishmaniasis due to <i>Leishmania braziliensis</i> , <i>Leishmania guyanensis</i> , or <i>Leishmania panamensis</i> , (c) Mucosal leishmaniasis due to <i>Leishmania braziliensis</i> .
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Request will be authorized for 28 days.
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

INCRELEX

Products Affected

- INCRELEX

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an endocrinologist.
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	For growth failure due to severe primary insulin-like growth factor-1 (IGF-1) deficiency or growth hormone (GH) gene deletion in patients who have developed neutralizing antibodies to GH, patient meets all of the following prior to beginning therapy with the requested drug - Initial: (1) height 3 or more standard deviations (SDs) below the mean for children of the same age and gender AND (2) basal IGF-1 level 3 or more SDs below the mean for children of the same age and gender AND (3) provocative growth hormone test showing a normal or elevated growth hormone level. For growth failure due to severe primary IGF-1 deficiency or GH gene deletion in patients who have developed neutralizing antibodies to GH - Continuation of therapy: patient has positive clinical response.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

JAKAFI

Products Affected

- JAKAFI

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	Prescriber must be an oncologist or specialist for submitted diagnosis.
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	For essential thrombocythemia - Initial: patient had an inadequate response or loss of response to hydroxyurea, interferon therapy, or anagrelide. Continuation of therapy: patient has positive clinical response to treatment. For graft-versus-host disease (GVHD) - Initial: Trial of, contraindication to, or medical reason for not using a systemic corticosteroid. For continuation of therapy for treatment of GVHD: documentation of clinical benefit from use of the drug (i.e. symptom improvement, reduction in corticosteroid dose). For polycythemia vera - Initial: patient had an inadequate response or intolerance to interferon therapy or hydroxyurea. Continuation of therapy: patient has positive clinical response to treatment.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

JUXTAPID

Products Affected

- JUXTAPID ORAL CAPSULE 10 MG, 20 MG, 30 MG, 5 MG

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	The member has a documented diagnosis of homozygous familial hypercholesterolemia (HoFH) as confirmed by one of the following: (1) generic confirmation of two mutant alleles at the LDLR, APOB, PCSK9 or LDLRAP1 gene locus OR (2) untreated LDL-C greater than 400 mg/dL or treated LDL cholesterol greater than or equal to 300 mg/DL or treated non-HDL cholesterol greater than or equal to 330 mg/DL together with either of the following: (a) xanthoma prior to ten years of age, (b) evidence of heterozygous familial hypercholesterolemia (HeFH) in both parents.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a cardiologist, endocrinologist or lipid specialist
Coverage Duration	Initial: 6 months. Continuation of therapy: end of contract year.
Other Criteria	Initial: Trial and failure of, contraindication, or medical reason for not using both of the following: (1) Lipid lowering therapy (i.e., statins, ezetimibe, bile acid sequestrants, etc.) AND (2) Praluent and/or Repatha. Reauthorization: Documentation of reduction in LDL level since initiation of therapy.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

KALYDECO

Products Affected

- KALYDECO

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent use with Orkambi, Symdeko, or Trikafta.
Required Medical Information	Documentation of CFTR gene that is responsive to ivacaftor treatment.
Age Restrictions	1 month of age or older.
Prescriber Restrictions	Prescribed by or in consultation with a pulmonologist or a provider specializing in treatment of CF.
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	Cystic Fibrosis - Initial: (1) patient must have a mutation in the CFTR gene that is considered to be a pathogenic or likely pathogenic variant (ex: E56K, P67L, M952T, etc.), AND (2) patient has positive newborn screening test, OR family history of cystic fibrosis OR clinical presentation consistent with signs and symptoms of cystic fibrosis (ex: pulmonary function tests consistent with obstructive airways, excess sputum production, etc.), AND (3) patient has evidence of abnormal cystic fibrosis transmembrane conductance regulator function as demonstrated by elevated sweat chloride test, OR abnormal nasal potential difference, OR two cystic fibrosis-causing cystic fibrosis transmembrane conductance regulator mutations. Continuation of therapy: patient has positive clinical response to treatment.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

Formulary ID 26323

Last Updated: 10/15/2025

KERENDIA

Products Affected

- KERENDIA

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off-Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

KEVZARA

Products Affected

- KEVZARA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	Specialist for submitted diagnosis.
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	For RA: Either 1) Trial of, medical reason for not using, or contraindication to 2 of the following: Enbrel, an adalimumab product, or Xeljanz or 2) If utilized within the past 120 days, approve for continuation of therapy. For polymyalgia rheumatica (PMR): Trial of, medical reason for not using, or contraindication to corticosteroids. For pJIA: Either 1) Trial of, medical reason for not using, or contraindication to 2 of the following: Enbrel, an adalimumab product, or Xeljanz or 2) If utilized within the past 120 days, approve for continuation of therapy.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

KINERET

Products Affected

- KINERET SUBCUTANEOUS
SOLUTION PREFILLED SYRINGE

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with specialist for submitted diagnosis.
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	Rheumatoid Arthritis (RA) - Initial: trial of, medical reason for not using, or contraindication to 2 of the following: Enbrel, an adalimumab product, or Xeljanz. Continuation of therapy: patient has positive clinical response to treatment. Neonatal-onset multisystem inflammatory disease (NOMID) or deficiency of interleukin-1 receptor antagonist (DIRA): approve.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

LEQSELVI

Products Affected

- LEQSELVI

PA Criteria	Criteria Details
Exclusion Criteria	Absolute lymphocyte count less than 500 cells/mm ³ , absolute neutrophil count less than 1,000 cells/mm ³ or hemoglobin level less than 8 g/dl.
Required Medical Information	Initial: (1) documented diagnosis via chart notes of severe alopecia areata AND (2) patient is not receiving in combination with either of the following: (i) Targeted immunomodulator (i.e. Enbrel, Cimzia, Simponi, Orencia, an adalimumab product, Xeljanz) OR (ii) potent immunosuppressant. Continuation of therapy: documentation of positive clinical response to treatment.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Initial: 6 months. Continuation of therapy: end of contract year.
Other Criteria	Documentation of confirmed diagnosis and other causes of hair loss have been ruled out.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

LITFULO

Products Affected

- LITFULO

PA Criteria	Criteria Details
Exclusion Criteria	Absolute lymphocyte count less than 500 cells/mm ³ or platelet count less than 100,000 cells/mm ³ .
Required Medical Information	Initial: (1) documented diagnosis via chart notes of severe alopecia areata AND (2) patient is not receiving in combination with either of the following: (i) Targeted immunomodulator (i.e. Enbrel, Cimzia, Simponi, Orencia, an adalimumab product, Xeljanz) OR (ii) potent immunosuppressant. Continuation of therapy: documentation of positive clinical response to treatment.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Initial: 6 months. Continuation of therapy: end of contract year.
Other Criteria	Documentation of confirmed diagnosis and other causes of hair loss have been ruled out.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

LIVMARLI

Products Affected

- LIVMARLI

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Initial: (1) documented diagnosis of Alagille Syndrome (ALGS) with molecular genetic testing confirming mutations in the JAG1 or NOTCH2 gene AND (2) documentation of one of the following, (i) total serum bile acid greater than 3x the upper limit of normal (ULN) OR (ii) conjugated bilirubin greater than 1mg/dL OR (iii) Gammaglutamyl transpeptidase (GGT) greater than 3x ULN OR (iv) unexplainable fat soluble vitamin deficiency AND (3) patient is experiencing moderate to severe cholestatic pruritus AND (4) patient has had an inadequate response to one of the following treatments used for the relief of pruritus: antihistamine, ursodeoxycholic acid (i.e. Ursodiol), rifampin, bile acid sequestrants (i.e. Questran, Welchol). For new starts for Progressive Familial Intrahepatic Cholestasis (PFIC): (1) PFIC type 1, 2, 3, 4 or 6, with confirmed biallelic mutations via genetic testing AND (2) Documentation that patient does not have an ABCB11 variant that results in non-functional or complete absence of bile salt export pump protein. Continuation of therapy: (1) clinical improvement in pruritis AND (2) reduction in serum bile acid level from baseline AND (3) attestation of monitoring of hepatic enzymes for decompensation.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a hepatologist or gastroenterologist.
Coverage Duration	Initial: 6 months. Continuation of therapy: end of contract year.
Other Criteria	For new starts: 1) Trial of, contraindication to, or medical reason for not using both of the following: cholestyramine AND rifampin. 2) Prescriber attests that the member has cholestasis 3) Baseline serum bile acid level is provided. 4) Documentation of patients weight. For continuation of therapy or reauthorization: 1) Documentation submitted indicating the member has had all of the following: an improvement in pruritis (e.g. improved observed scratching, decreased sleep disturbances/nighttime awakenings

PA Criteria	Criteria Details
	due to scratching, etc.) AND reduction in serum bile acid level from baseline. 2) Prescriber attests that patient has had no evidence of hepatic decompensation (e.g. variceal hemorrhage, ascites, hepatic encephalopathy, portal hypertension, etc.). 3) Documentation of patients weight.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

LIVTENCITY

Products Affected

- LIVTENCITY

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Cytomegalovirus (CMV): (1) Documented diagnosis of CMV infection AND (2) Member is a recipient of one of the following: (a) hematopoietic stem cell transplant, (b) solid organ transplant AND (3) patient has tried and failed, has contraindication to or is intolerant to treatment with valganciclovir, ganciclovir, cidofivir, or foscarnet AND (4) patient weighs greater than or equal to 35 kg.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a transplant specialist, infectious disease specialist, oncologist, hematologist or other appropriate specialist.
Coverage Duration	Request will be authorized for 8 weeks.
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

LODOCO

Products Affected

- LODOCO

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Initial: (1) documentation patient has established atherosclerotic disease or multiple risk factors for cardiovascular disease AND (2) documentation that patient does not have pre-existing blood dyscrasias (i.e. leukopenia, thrombocytopenia) AND (3) patient does not have renal failure (CrCl less than 15 ml/min) or severe hepatic impairment AND (4) previous trial of or intolerance to colchicine.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a cardiologist.
Coverage Duration	Initial: 6 months. Continuation of therapy: end of contract year.
Other Criteria	Documentation that patient has established atherosclerotic disease or multiple risk factors for cardiovascular disease AND documentation that patient does not have pre-existing blood dyscrasias (ex. leukopenia, thrombocytopenia) and patient does not have renal failure (CrCl less than 15 ml/min) or severe hepatic impairment
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

LUCEMYRA

Products Affected

- *lofexidine hcl*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Request will be authorized for 14 days.
Other Criteria	Patient must have trial of, contraindication to, or medical reason for not using clonidine.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

LUPKYNIS

Products Affected

- LUPKYNIS

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off-Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

LYBALVI

Products Affected

- LYBALVI

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent use with opioids.
Required Medical Information	Schizophrenia - Initial: (1) diagnosis of schizophrenia AND (2) documented trial of or intolerance or contraindication to at least two generic antipsychotics, one of which must be generic olanzapine (at maximally tolerated dose) AND (3) attestation from the provider that the patient has had an opioid-free period of a minimum of 7 days after last use of shorting-acting opioids and 14 days from last use of long-acting opioids before initiating .Continuation of therapy: patient has positive clinical response to treatment. Bipolar I Disorder - Initial: (1) patient must have a diagnosis of bipolar I disorder AND (2) documented trial of or intolerance or contraindication to olanzapine and at least one other generic therapy (i.e. lamotrigine, lithium, valproate, quetiapine, etc.) AND (3) attestation from the provider that the patient has had an opioid-free period of a minimum of 7 days after last use of shorting-acting opioids and 14 days from last use of long-acting opioids before initiating. Continuation of therapy: patient has positive clinical response to treatment.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

MAVYRET

Products Affected

- MAVYRET ORAL PACKET
- MAVYRET ORAL TABLET

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Detectable HCV RNA viral load prior to treatment within 6 months of request. In addition, documentation of treatment history, and if cirrhotic, documentation of compensated or decompensated cirrhosis.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Request will be authorized for 8-16 weeks as per AASLD-IDSA guidance.
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

METHOTREXATE ORAL SOLUTION

Products Affected

- JYLAMVO
- XATMEP

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	Prescriber must be an oncologist, a rheumatologist, a dermatologist, or other appropriate specialist
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	Polyarticular Juvenile Idiopathic Arthritis (pJIA) - Initial: (1) patient had been diagnosed with pJIA AND (2) patient had tried, intolerant or has medical reason for not using at least one non-steroidal anti-inflammatory agents (NSAIDs) AND methotrexate.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

METHYLTESTOSTERONE

Products Affected

- methyltestosterone oral*

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off-Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

METYROSINE

Products Affected

- *metyrosine*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Documentation of one of the following: 1) Concurrent use of alpha adrenergic blockers, 2) Medical reason for being unable to use an alpha adrenergic blocker, OR 3) Patient is not a candidate for surgical resection and requires long term treatment with metyrosine.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an endocrinologist or a provider who specializes in the management of pheochromocytoma.
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	Initial: patient has tried a selective alpha blocker (i.e. doxazosin, prazosin or terazosin). Continuation of therapy: approve.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

MIFEPRISTONE

Products Affected

- *mifepristone oral tablet 300 mg*

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent use with simvastatin, lovastatin, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an endocrinologist or a provider who specializes in the treatment of Cushing's syndrome.
Coverage Duration	Cushing's Syndrome: end of contract yr.
Other Criteria	Endogenous Cushing's Syndrome - Initial: (1) patient is not a candidate for surgery or surgery has not been curative AND (2) requested drug is being used to control hyperglycemia secondary to hypercortisolism in patients who have Type 2 Diabetes Mellitus (T2DM) or glucose intolerance. Continuation of therapy: patient has positive clinical response to treatment.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

MIGLUSTAT

Products Affected

- *miglustat*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Initial: (1) documentation of diagnosis for mild to moderate type 1 Gaucher disease. Continuation of therapy: documentation of positive clinical response (i.e. increased platelet count, improvement in anemia, PFT's).
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a specialist in treatment of Gaucher's disease.
Coverage Duration	Initial: 6 months. Continuation of therapy: end of contract year.
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

MULTIPLE SCLEROSIS AGENTS

Products Affected

- BAFIERTAM
- BETASERON SUBCUTANEOUS KIT
- *dimethyl fumarate oral capsule delayed release 120 mg, 240 mg*
- *dimethyl fumarate starter pack oral capsule delayed release therapy pack*
- *fingolimod hcl*
- *glatiramer acetate subcutaneous solution prefilled syringe 20 mg/ml, 40 mg/ml*
- GLATOPA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 20 MG/ML, 40 MG/ML
- KESIMPTA
- MAVENCLAD (10 TABS)
- MAVENCLAD (4 TABS)
- MAVENCLAD (5 TABS)
- MAVENCLAD (6 TABS)
- MAVENCLAD (7 TABS)
- MAVENCLAD (8 TABS)
- MAVENCLAD (9 TABS)
- MAYZENT
- MAYZENT STARTER PACK ORAL TABLET THERAPY PACK 12 X 0.25 MG, 7 X 0.25 MG
- PONVORY
- PONVORY STARTER PACK
- REBIF REBIDOSE SUBCUTANEOUS SOLUTION AUTO-INJECTOR
- REBIF REBIDOSE TITRATION PACK SUBCUTANEOUS SOLUTION AUTO-INJECTOR
- REBIF SUBCUTANEOUS SOLUTION PREFILLED SYRINGE
- REBIF TITRATION PACK SUBCUTANEOUS SOLUTION PREFILLED SYRINGE
- TASCENSO ODT
- *teriflunomide*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with specialist for submitted diagnosis.
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	Requests for Bafiertam, Betaseron, Kesimpta, Mavenclad, Mayzent, Ponvory, Rebif, Tascenso - Initial: patient has tried and failed, contraindication or medical reason for not using at least two of the

PA Criteria	Criteria Details
	following: dalfampridine ER, dimethyl fumarate, fingolimod, glatiramer, glatopa, or teriflunomide.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

MYFEMBREE

Products Affected

- MYFEMBREE

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off-Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

NASAL ANTISEIZURE AGENTS

Products Affected

- NAYZILAM
- VALTOCO 10 MG DOSE
- VALTOCO 15 MG DOSE NASAL LIQUID THERAPY PACK 2 X 7.5 MG/0.1ML
- VALTOCO 20 MG DOSE NASAL LIQUID THERAPY PACK 2 X 10 MG/0.1ML
- VALTOCO 5 MG DOSE

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off-Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	No

NITISINONE

Products Affected

- *nitisinone*
- ORFADIN ORAL SUSPENSION

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	Prescriber must be a geneticist, metabolic specialist, hepatologist, or liver transplant specialist.
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	Hereditary Tyrosinemia Type 1 (HT-1): diagnosis was confirmed by genetic testing confirming a mutation of the FAH gene OR elevated levels of succinylacetone.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

NON-AMPHETAMINE CENTRAL NERVOUS SYSTEM AGENTS

Products Affected

- *armodafinil oral tablet 150 mg, 200 mg, 250 mg, 50 mg*
- *modafinil oral tablet 100 mg, 200 mg*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	18 years of age or older.
Prescriber Restrictions	N/A
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	For excessive sleepiness associated with narcolepsy - Initial: diagnosis has been confirmed by sleep lab evaluation. Continuation of therapy: patient has positive clinical response to treatment. For excessive sleepiness associated with obstructive sleep apnea (OSA) - Initial: diagnosis has been confirmed by polysomnography. Continuation of therapy: patient has positive clinical response to treatment.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

NUCALA

Products Affected

- NUCALA SUBCUTANEOUS SOLUTION AUTO-INJECTOR
- NUCALA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 100 MG/ML, 40 MG/0.4ML
- NUCALA SUBCUTANEOUS SOLUTION RECONSTITUTED

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off-Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

NUEDEXTA

Products Affected

- NUEDEXTA

PA Criteria	Criteria Details
Exclusion Criteria	Complete atrioventricular (AV) block without implanted pacemaker, or at high risk of complete AV block. History of heart failure. Concomitant use with MAOIs or use of MAOIs within 14 days. Concomitant use with drugs containing quinidine, quinine, or mefloquine. History of quinine-, mefloquine-, dextromethorphan/quinidine-, or quinidine-induced thrombocytopenia, hepatitis, bone marrow depression, or lupus-like syndrome. Non-Part D indications.
Required Medical Information	Confirmation diagnosis is for Part D indication.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a neurologist or psychiatrist.
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

NUPLAZID

Products Affected

- NUPLAZID ORAL CAPSULE
- NUPLAZID ORAL TABLET 10 MG

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	For hallucinations and delusions associated with Parkinson's disease psychosis: documented diagnosis of Parkinson's disease must be made prior to the onset of psychotic symptoms.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

NURTEC ODT

Products Affected

- NURTEC

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off-Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

OCALIVA

Products Affected

- OCALIVA

PA Criteria	Criteria Details
Exclusion Criteria	Members with decompensated cirrhosis, a prior decompensation event, compensated cirrhosis who have evidence of portal hypertension, or complete biliary obstruction.
Required Medical Information	For new starts: 1) Lab results for baseline ALT/AST, alkaline phosphatase (ALP), and bilirubin within 90 days of request AND 2) patient has no evidence of cirrhosis OR patient has compensated cirrhosis without evidence of portal hypertension.
Age Restrictions	Initial therapy only: 18 years of age or older.
Prescriber Restrictions	Initial therapy only: prescribed by or in consultation with a gastroenterologist, hepatologist, or liver transplant provider.
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	Primary biliary cholangitis (PBC) - Initial: (1) patient has a diagnosis of PBC as defined by two of the following tests: (i) alkaline phosphatase (ALP) elevated above the upper limit of normal as defined by normal laboratory reference values OR (ii) positive anti-mitochondrial antibodies (AMAs) or other PBC-specific auto-antibodies (including sp100 or gp210) OR if AMA is negative (iii) histologic evidence of primary biliary cholangitis (PBC) from a liver biopsy AND (2) patient has been receiving ursodiol therapy for greater than or equal to 1 year and has had an inadequate response OR patient is unable to tolerate ursodiol therapy. Continuation of therapy: patient has positive clinical response to Ocaliva therapy (i.e. improved biochemical markers of PBC) AND patient has no cirrhosis OR patient has compensated cirrhosis without evidence of portal hypertension.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

OCREVUS

Products Affected

- OCREVUS

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	18 years of age and older.
Prescriber Restrictions	Specialist for submitted diagnosis.
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	For new starts for Clinically Isolated Syndrome (CIS), Relapsing Remitting Multiple Sclerosis (RRMS), or Secondary Progressive Multiple Sclerosis (SPMS): 1) Documentation of CIS, RRMS, or SPMS AND 2) The member must have a documented trial of, contraindication to, or medical reason for not using both dimethyl fumarate AND glatiramer or Glatopa. For new starts for Primary Progressive Multiple Sclerosis (PPMS): Documentation of PPMS. For all continuation of therapy or reauthorization: Documentation that the prescriber has evaluated the member and recommends continuation of therapy (clinical benefit).
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

OCTREOTIDE

Products Affected

- *octreotide acetate injection solution 100 mcg/ml, 1000 mcg/ml, 200 mcg/ml, 50 mcg/ml, 500 mcg/ml*
- *octreotide acetate intramuscular*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Acromegaly - Initial: (1) documented diagnosis of acromegaly AND (2) patient has a high pretreatment insulin-like growth factor-1 (IGF-1) level for age and/or gender based on the laboratory reference range AND (3) patient had an inadequate or partial response to surgery or radiotherapy OR there is a medical reason for why the patient has not had surgery or radiotherapy. Continuation of therapy: patient's IGF-1 level has decreased or normalized since Initial of therapy.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with specialist for submitted diagnosis.
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	Continuation of therapy or reauthorization: documentation of clinical improvement with therapy.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

OFEV

Products Affected

- OFEV

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Chronic fibrosing interstitial lung disease - Initial: [Note: documentation required] (1) documented diagnosis AND (2) forced vital capacity is greater than or equal to 45 percent of the predicted value AND (3) patient has fibrosing lung disease impacting more than 10 percent of lung volume on high-resolution computed tomography AND (3) patient has clinical signs of progression. Continuation of therapy: patient has positive clinical response to treatment. Interstitial lung disease associated with systemic sclerosis - Initial: [Note: documentation required] (1) documented diagnosis AND (2) FVC is greater than or equal to 40 percent of the predicted value and the diagnosis is confirmed by high-resolution computed tomography. Continuation of therapy: patient has positive clinical response to treatment. Idiopathic pulmonary fibrosis (IPF) - Initial: [Note: documentation required] (1) documented diagnosis AND (2) FVC greater than or equal to 40 percent of the predicted value AND (3) IPF must be diagnosed with either findings on high-resolution computed tomography (HRCT) indicating usual interstitial pneumonia (UIP) or surgical lung biopsy demonstrating UIP. Continuation of therapy: patient has positive clinical response to treatment.
Age Restrictions	18 years of age or older.
Prescriber Restrictions	IPF: prescribed by or in consultation with a pulmonologist. Interstitial lung disease associated with systemic sclerosis: prescribed by or in consultation with a pulmonologist or rheumatologist.
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	For a diagnosis of idiopathic pulmonary fibrosis: 1) Documentation of disease as demonstrated on a high resolution CT scan or through lung biopsy and 2) Documented trial of, contraindication to, or medical reason for not using pirfenidone. For a diagnosis of systemic sclerosis-associated interstitial lung disease (SSc-ILD): documented trial of, contraindication to, or medical reason for not using mycophenolate mofetil or

PA Criteria	Criteria Details
	cyclophosphamide. For a diagnosis of chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype: documentation is provided confirming diagnosis.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

OPSUMIT

Products Affected

- OPSUMIT

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Pulmonary arterial hypertension (PAH) World Health Organization (WHO) Group I - Initial: [Note: documentation required] (1) PAH was confirmed by right heart catheterization AND (2) pretreatment mean pulmonary arterial pressure is greater than 20 mmHg AND (3) pretreatment pulmonary capillary wedge pressure is less than or equal to 15 mmHg AND (4) pretreatment pulmonary vascular resistance is greater than or equal to 3 Wood units. Continuation of therapy: patient has positive clinical response to treatment.
Age Restrictions	N/A
Prescriber Restrictions	Prescriber must be a pulmonologist or cardiologist
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	Trial of, contraindication to, or medical reason for not using sildenafil.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

ORAL ANTIPSYCHOTICS

Products Affected

- CAPLYTA
- COBENFY
- COBENFY STARTER PACK
- FANAPT
- FANAPT TITRATION PACK A
- FANAPT TITRATION PACK B ORAL TABLET
- FANAPT TITRATION PACK C ORAL TABLET
- OPIPZA ORAL FILM 10 MG, 2 MG, 5 MG
- VRAYLAR ORAL CAPSULE

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	For schizophrenia, manic or mixed episodes associated with bipolar I disorder, major depressive disorder associated with bipolar I or II disorder, adjunctive treatment of major depressive disorder, irritability associated with autistic disorder or treatment of Tourette's disorder: trial of, contraindication to, or medical reason for not using two generic antipsychotics. If the request is for Vraylar for major depressive disorder: provider attestation that the member is concurrently using an antidepressant.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

ORENCIA

Products Affected

- ORENCIA CLICKJECT
- ORENCIA INTRAVENOUS
- ORENCIA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 125 MG/ML, 50 MG/0.4ML, 87.5 MG/0.7ML

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent use with a Biologic DMARD or Targeted Synthetic DMARD.
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with specialist for submitted diagnosis.
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	Polyarticular juvenile idiopathic arthritis (pJIA): trial of, medical reason for not using, or contraindication to 2 of the following: Enbrel, an adalimumab product, or Xeljanz. Continuation of therapy: patient has positive clinical response to treatment. Psoriatic arthritis (PsA): trial of, medical reason for not using, or contraindication to 2 of the following therapies: an ustekinumab product, Cosentyx, Tremfya, Xeljanz, Enbrel or an adalimumab product. Continuation of therapy: patient has positive clinical response to treatment. Rheumatoid arthritis (RA) - Initial: trial of, medical reason for not using, or contraindication to 2 of the following: Enbrel, an adalimumab product or Xeljanz. Continuation of therapy: patient has positive clinical response to treatment. Acute graft versus host disease: attestation member is taking in combination with a calcineurin inhibitor and methotrexate. Continuation of therapy: patient has positive clinical response to treatment.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Formulary ID 26323

Last Updated: 10/15/2025

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

ORIAHNN

Products Affected

- ORIAHNN

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off-Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

ORILISSA

Products Affected

- ORILISSA

PA Criteria	Criteria Details
Exclusion Criteria	Patient has history of osteoporosis or hepatic impairment.
Required Medical Information	Initial: (1) documented diagnosis of moderate to severe pain associated with endometriosis AND (2) patient is premenopausal AND (3) patient has history of trial and failure (i.e. inadequate pain relief), contraindication or intolerance to a trial of at least one analgesic (i.e. ibuprofen, meloxicam, naproxen) AND (4) patient has history of trial and failure, contraindication, or intolerance after a trial of at least one of the following: hormonal contraceptives, progestins, gonadotropin-releasing hormone (GnRH) agonists (i.e. Lupron Depot), OR danazol. Continuation of therapy: (1) treatment does not exceed the eligible maximum lifetime treatment duration of 2 years for 150mg tablet or 6 months for 200mg tablet AND (2) documentation of patient experiencing positive clinical positive response to treatment.
Age Restrictions	N/A
Prescriber Restrictions	Prescriber must be an OB, gynecologist or reproductive endocrinologist.
Coverage Duration	Initial: 6 months. Continuation of therapy: end of contract year.
Other Criteria	Trial of, contraindication to, or medical reason for not using the following concurrently for endometriosis: analgesic pain reliever (e.g. NSAIDs, COX-2 inhibitors) AND either combined estrogen-progestin oral contraceptive, progestin (e.g. medroxyprogesterone acetate, norethindrone), gonadotropin-releasing hormone (GnRH) agonists (e.g. Lupron Depot), OR danazol. For continuation of therapy or reauthorization both of the following are required: 1) Treatment does not exceed the eligible maximum lifetime treatment duration of 2 years for 150mg tablet or 6 months for 200mg tablet, and 2) Documentation has been provided that the member has obtained clinical benefit from the medication.
Indications	All Medically-accepted Indications.

PA Criteria	Criteria Details
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

ORKAMBI

Products Affected

- ORKAMBI ORAL PACKET
- ORKAMBI ORAL TABLET

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent use with Kalydeco, Symdeko, or Trikafta.
Required Medical Information	Cystic Fibrosis (CF) - Initial: documented diagnosis confirmed by homozygous for the Phe508del (F508del) mutation in the CFTR gene (meaning the patient has two copies of the Phe508del mutation). Continuation of therapy: patient has positive clinical response to treatment.
Age Restrictions	1 year of age or older.
Prescriber Restrictions	Prescribed by or in consultation with a pulmonologist or a provider who specializes in treatment of CF.
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

OTEZLA

Products Affected

- OTEZLA ORAL TABLET
- OTEZLA ORAL TABLET THERAPY PACK

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent Use with a Biologic or with a Targeted Synthetic Disease Modifying Antirheumatic Drugs (DMARD).
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with specialist for submitted diagnosis.
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	Psoriasis, moderate to severe - Initial: trial of, medical reason for not using, or contraindication to 2 of the following therapies: an ustekinumab product, Tremfya, Enbrel, or an adalimumab product. Continuation of therapy: patient has positive clinical response to treatment. Psoriatic arthritis (PsA) - Initial: trial of, medical reason for not using, or contraindication to 2 of the following therapies: an ustekinumab product, Tremfya, Xeljanz, Enbrel or an adalimumab product. Continuation of therapy: patient has positive clinical response to treatment. Bechet's Syndrome or mild psoriasis: Approve.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

OXERVATE

Products Affected

- OXERVATE

PA Criteria	Criteria Details
Exclusion Criteria	Treatment duration greater than 16 weeks per affected eye(s).
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by an ophthalmologist or an optometrist.
Coverage Duration	Initial: 8 weeks. Continuation of therapy: additional 8 weeks.
Other Criteria	Initial: confirmed diagnosis. Continuation of therapy: patient has previously received less than or equal to 8 weeks of treatment per affected eye(s) and the patient has a recurrence of neurotrophic keratitis.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

OXYCODONE ER

Products Affected

- OXYCONTIN ORAL TABLET ER 12 MG, 20 MG, 30 MG, 40 MG, 60 MG, 80 MG
HOUR ABUSE-DETERRENT 10 MG, 15 MG

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	Patient is being treated for cancer related diagnoses (i.e. members being treated for cancer-related pain including those undergoing active cancer treatment and cancer survivors with chronic pain who have completed cancer treatment), sickle cell diagnoses, those in hospice care, or receiving palliative care will be excluded from the concurrent benzodiazepine and muscle relaxant therapy requirement. Initial: (1) documented history of receiving an immediate-release opioid, (2) documented trial of, contraindication to, or medical reason for not using long-acting morphine sulfate, (3) if patient is on concurrent benzodiazepines and/or muscle relaxant therapy, the prescriber attests that concurrent therapy is medically necessary AND (4) patient is not being treated for substance abuse with buprenorphine-containing products. Continuation of therapy: (1) pain has been assessed within the last 6 months AND (2) patient has demonstrated clinical improvement in pain and function on current medication regimen AND (3) if patient is on concurrent benzodiazepines and/or muscle relaxant therapy, the prescriber attests that concurrent therapy is medically necessary AND (4) patient is not being treated for substance abuse with buprenorphine-containing products.
Indications	All Medically-accepted Indications.

PA Criteria	Criteria Details
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

PCSK9 INHIBITORS

Products Affected

- REPATHA
- REPATHA SURECLICK

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis and labs.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a cardiologist, endocrinologist, or a provider who focuses in the treatment of CV risk management and/or lipid disorders.
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	Heterozygous familial hypercholesterolemia (HeFH) - Initial: (1) HeFH diagnosis AND (2) tried or has contraindication to high intensity statin (i.e. minimum of atorvastatin 40 mg daily or rosuvastatin 20 mg daily or higher) AND (3) LDL greater than or equal to 70 mg/dL unless the patient is determined to be statin intolerant (i.e. rhabdomyolysis or pt experienced skeletal related muscle symptoms while receiving separate trials of atorvastatin and rosuvastatin where symptoms resolved upon discontinuation of statin). Hyperlipidemia with ASCVD - Initial: (1) pt has one of the following conditions: prior MI, history of ACS, diagnosis of angina, history of TIA, PAD, undergone a coronary or other arterial revascularization procedure AND (2) tried or has contraindication to high intensity statin (defined above) AND (3) ezetimibe concomitantly and LDL-C remains greater than or equal to 55 mg/dL unless the patient is determined to be statin intolerant (defined above). Homozygous familial hypercholesterolemia (HoFH) - Initial: (1) diagnosis confirmed w/ genetic test (i.e. two mutant alleles at the APOB, LDLR, LDLRAP1 or PCSK9 gene locus) OR (2) pretreatment LDL greater than 400 mg/dL OR (3) treated LDL greater than or equal to 300 mg/dL (note: pretreatment not including Repatha, Praluent, Juxtapid, Nexletol or Nexlizet) OR (4) patient has clinical manifestations of HoFH (i.e. arcus cornea, cutaneous xanthomas, tendon xanthomas, tuberous xanthomas and/or xanthelasma)

PA Criteria	Criteria Details
	AND (5) tried or has contraindication to high intensity statin (defined above).Primary hyperlipidemia (not associated with ASCVD, HeFH, or HoFH) - Initial: (1) tried or has contraindication to high intensity statin (defined above) AND (2) LDL remains 100 mg/dL or higher unless statin intolerant (defined above). Continuation for all indications: patient has positive clinical response to treatment due to elevated LDLs.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

PEGINTERFERON

Products Affected

- PEGASYS SUBCUTANEOUS SOLUTION 180 MCG/ML
- PEGASYS SUBCUTANEOUS SOLUTION PREFILLED SYRINGE

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	For Hepatitis C: 1) Labs within 3 months of request: liver function tests and detectable HCV RNA viral load. 2) Documentation of genotype, treatment history, and if cirrhotic, documentation of compensated or decompensated cirrhosis. For Hepatitis B: 1) Labs within 3 months of request: ALT/AST, and 2) HBeAg status. For polycythemia vera, approve.
Age Restrictions	N/A
Prescriber Restrictions	Prescriber must be a gastroenterologist, hepatologist, infectious disease doctor or transplant specialist.
Coverage Duration	Request will be authorized for 24 to 48 weeks as defined by compendia.
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

PENICILLAMINE

Products Affected

- *penicillamine oral tablet*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with specialist for submitted diagnosis.
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	Rheumatoid arthritis (RA) - Initial: patient has trial, intolerance or medical reason for not using at least 2 of the following: Enbrel, an adalimumab product, or Xeljanz. Wilson's disease - Initial: documented diagnosis confirmed by one of the following methods (1 or 2) (1) genetic testing showing biallelic pathogenic ATP7B mutations (pt can be asymptomatic or symptomatic) OR (2) at least two of the following (i) serum ceruloplasmin level less than 20 mg/dL, (ii) presence of Kayser-Fleischer rings, (iii) 24-hour urinary copper greater than 40 mcg/24 hours, or (iv) liver biopsy findings consistent with Wilson's disease. For other indications, approve. Continuation of therapy for all indications: patient has a positive clinical response to therapy.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

PERSERIS

Products Affected

- PERSERIS

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	The member has a documented history of receiving oral risperidone without any clinically significant side effects.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	Trial and failure of, contraindication, or medical reason for not using at least two of the following: Abilify Maintena, Abilify Asimtufii, Risperidone Microsphere, Invega Sustenna, Invega Trinza, and Invega Hafyera.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

PHENOXYBENZAMINE

Products Affected

- *phenoxybenzamine hcl oral*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Initial: (1) patient has documented diagnosis of pheochromocytoma AND (2) patient has trial, failure, intolerance or contraindication to at least one alpha-1 selective adrenergic receptor blocker (i.e. doxazosin).
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an endocrinologist, endocrine surgeon, hematologist, or oncologist.
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	Trial of, contraindication to, or medical reason for not using doxazosin.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

PIRFENIDONE

Products Affected

- *pirfenidone oral capsule*
- *pirfenidone oral tablet 267 mg, 534 mg, 801 mg*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Idiopathic pulmonary fibrosis - Initial: [Note: documentation required] (1) a high-resolution computed tomography (HRCT) study of the chest or a lung biopsy reveals the usual interstitial pneumonia (UIP) pattern OR (2) HRCT study of the chest reveals a result other than the UIP pattern (i.e. probable UIP, indeterminate for UIP) AND (3) the diagnosis is supported either by a lung biopsy OR by a multidisciplinary discussion between at least a radiologist and pulmonologist who are experienced in idiopathic pulmonary fibrosis if a lung biopsy has not been conducted. Continuation of therapy: patient has positive clinical response to therapy.
Age Restrictions	18 years of age or older.
Prescriber Restrictions	Prescribed by or in consultation with a pulmonologist.
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

POSACONAZOLE

Products Affected

- *posaconazole oral suspension*
- *posaconazole oral tablet delayed release*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Documented diagnosis of medically accepted indication. The requested drug will be used orally. For prophylaxis of invasive Aspergillus and Candida infections: patient weighs greater than 40 kilograms.
Age Restrictions	Prophylaxis of Invasive Aspergillus and Candida Infections: 2 years of age or older. Treatment of Invasive Aspergillosis: 13 years of age or older.
Prescriber Restrictions	Documentation of a consultation with an infectious disease specialist, a transplant specialist, or an oncologist.
Coverage Duration	Request will be authorized for 6 months.
Other Criteria	For treatment of oropharyngeal candidiasis: trial of, contraindication to, or medical reason for not using fluconazole or itraconazole. For prophylaxis of invasive aspergillus infections due to being severely immunocompromised: trial of, contraindication to, or medical reason for not using voriconazole.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

PRETOMANID

Products Affected

- *pretomanid*

PA Criteria	Criteria Details
Exclusion Criteria	MDR-TB that is not treatment-intolerant or nonresponsive to standard therapy
Required Medical Information	Initial: (1) documented diagnosis of pulmonary extensively drug resistant (XDR) tuberculosis (TB) OR (2) treatment-intolerant or nonresponsive multidrug-resistant TB AND (3) will be used in combination with bedaquiline and linezolid AND (4) documentation of prior trial of or medical reason for not using first-line TB regimen containing isoniazid and rifampin.
Age Restrictions	18 years of age or older.
Prescriber Restrictions	Prescribed by or in consultation with infectious disease specialist, pulmonologist, or provider specializing in treatment of tuberculosis.
Coverage Duration	Request will be authorized for 26 weeks.
Other Criteria	Documentation of prior trial of or medical reason for not using first-line TB regimen containing isoniazid and rifampin.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

PREVYMIS

Products Affected

- PREVYMIS ORAL

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Prophylaxis of CMV disease in kidney transplant: (1) patient is CMV seronegative AND (2) the patient is a high risk recipient of kidney transplant. For prophylaxis of cytomegalovirus (CMV) infection or disease in hematopoietic stem cell transplant (HSCT): (1) patient is CMV seropositive AND (2) patient is a recipient of an allogeneic HSCT.
Age Restrictions	N/A
Prescriber Restrictions	Prescriber must be a hematologist, oncologist, infectious disease, or transplant specialist.
Coverage Duration	Request will be authorized for 7 months.
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

PROMACTA

Products Affected

- *eltrombopag olamine oral packet 12.5 mg, 25 mg*
- *eltrombopag olamine oral tablet 12.5 mg, 25 mg, 50 mg, 75 mg*

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off-Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

PYRIMETHAMINE

Products Affected

- *pyrimethamine oral*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with specialist for submitted diagnosis.
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	Toxoplasma gondii Encephalitis (Chronic Maintenance): patient is immunosuppressed. Toxoplasma gondii Encephalitis Prophylaxis (Primary): patient is immunosuppressed.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

PYRUKYND

Products Affected

- PYRUKYND
- PYRUKYND TAPER PACK

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Initial: (1) documented diagnosis of hemolytic anemia confirmed by the presence of chronic hemolysis (i.e. decreased haptoglobin, increased indirect bilirubin, elevated lactated dehydrogenase [LDH], increased reticulocyte count)AND (2) documented diagnosis of pyruvate kinase deficiency confirmed by molecular testing requiring all of the following: (i) patient is not homozygous for the c.1436G A (p.R479H) variant AND (ii) patient does not have 2 non-missense variants (without the presence of another missense variant) in the PKLR gene AND (iii) presence of at least 2 variant alleles in the pyruvate kinase liver and red blood cell (PKLR) gene, of which at least 1 was a missense variant AND (3) hemoglobin is less than or equal to 10g/dL AND (4) exclusion of other causes of hemolytic anemias (i.e. drugs, infections, toxins). Continuation of therapy: (1) documentation of clinical improvement (i.e. reduction in number of blood transfusions, increase or stabilization in hemoglobin level). If the criteria are not met, may authorize up to 14 days of a Pyrukynd Taper Pack to allow for tapering.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a hematologist.
Coverage Duration	Initial: 6 months. Continuation of therapy: end of contract year. Denial: 14 days for dose tapering.
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	No

QULIPTA

Products Affected

- QULIPTA

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off-Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

RADICAVA

Products Affected

- RADICAVA ORS
- RADICAVA ORS STARTER KIT

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a neurologist, a neuromuscular disease specialist, or a provider who specializes in the treatment of ALS.
Coverage Duration	Request will be authorized for 6 months.
Other Criteria	Amyotrophic lateral sclerosis (ALS) - Initial: (1) patient has definitive or probable ALS diagnosis (based on the application of the El Escorial or the revised Airlie House diagnostic criteria AND (2) patient has a minimum score of two points on each item of the ALS Functional Rating Scale - Revised (ALSFRS-R) [i.e. has retained most or all activities of daily living] AND (3) patient has a percent predicted FVC greater than or equal to 80% (i.e. has normal respiratory function) AND (4) patient has been diagnosed with ALS for less than or equal to 2 years. Continuation of therapy: patient has positive clinical response to treatment OR patient has tried Tiglutik or Exservan.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

RAVICTI

Products Affected

- RAVICTI

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Initial: (1) documented diagnosis of urea cycle disorder (UCD) AND (2) inadequate response to ONE of the following: (i) amino acid supplementation OR (ii) dietary protein restriction AND (3) trial and failure, contraindication, or intolerance to generic sodium phenylbutyrate. Continuation of therapy: patient has positive clinical response to treatment.
Age Restrictions	N/A
Prescriber Restrictions	Provider is a geneticist, metabolic specialist, gastroenterologist, hepatologist, or liver transplant specialist.
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	Trial of, contraindication to, or medical reason for not using sodium phenylbutyrate.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

RECORLEV

Products Affected

- RECORLEV

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Initial: (1) documented diagnosis of Cushing's disease AND (2) patient is not a candidate for pituitary surgery or surgery has not been curative AND (3) trial of, contraindication to, or medical reason for not using ketoconazole tablets.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with specialist for submitted diagnosis.
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	Trial of, contraindication to, or medical reason for not using ketoconazole tablets.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

RELISTOR

Products Affected

- RELISTOR ORAL
- RELISTOR SUBCUTANEOUS SOLUTION 12 MG/0.6ML, 12 MG/0.6ML (0.6ML SYRINGE), 8 MG/0.4ML
- RELISTOR SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 12 MG/0.6ML, 8 MG/0.4ML

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off-Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

REVCovi

Products Affected

- REVCovi

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Patient has diagnosis of adenosine deaminase severe combined immune deficiency (ADA-SCID) confirmed by one of the following: 1) documentation of deficiency or absence of adenosine deaminase OR 2) genetic testing revealing mutations in both alleles of the ADA1 gene AND/OR (3) biochemical testing showing less than 1% of ADA catalytic activity in red blood cells or in extracts of dried blood spots
Age Restrictions	N/A
Prescriber Restrictions	Prescriber must be an immunologist, geneticist, hematologist, oncologist, or provider who specializes in the treatment of ADA-SCID or related disorders.
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

REXULTI

Products Affected

- REXULTI

PA Criteria	Criteria Details
Exclusion Criteria	Dementia-related psychosis
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	For schizophrenia: trial of, contraindication to, or medical reason for not using two generic antipsychotics. For major depressive disorder: trial of, contraindication to, or medical reason for not using two generic antidepressants. For agitation due to dementia: 1) patient has documented diagnosis of Alzheimer's disease AND 2) medication will not be used on an "as needed" basis
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

REZDIFFRA

Products Affected

- REZDIFFRA

PA Criteria	Criteria Details
Exclusion Criteria	Patients with decompensated cirrhosis.
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a hepatologist, gastroenterologist, endocrinologist or specialist in the treatment of liver disease.
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	Initial therapy: (1) documented diagnosis of noncirrhotic nonalcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis, (2) documentation of stage F2 to F3 fibrosis as confirmed by a biopsy or a non-invasive test (NIT), (3) the drug is being prescribed at an FDA approved dose according to the member's weight and (4) prescriber attestation to providing lifestyle counseling on nutrition, exercise and avoiding excessive alcohol intake. For reauthorization: (1) the member has shown clinical benefit from the medication (e.g., the resolution of steatohepatitis and no worsening of liver fibrosis, or at least one stage improvement in liver fibrosis and no worsening of steatohepatitis), (2) the member continues to have a fibrosis stage of 3 or less and (3) the drug continues to be prescribed at an FDA approved dose according to the member's weight.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	No

REZUROCK

Products Affected

- REZUROCK

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off-Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

RUFINAMIDE

Products Affected

- *rufinamide oral suspension*
- *rufinamide oral tablet*

PA Criteria	Criteria Details
Exclusion Criteria	History of familial Short QT syndrome
Required Medical Information	N/A
Age Restrictions	1 year of age or older.
Prescriber Restrictions	Prescribed by or in consultation with a neurologist.
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	Initial: rufinamide is being used for adjunctive treatment. Continuation of therapy: patient has positive clinical response to treatment.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

RYKINDO

Products Affected

- RYKINDO

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	The member has a documented history of receiving oral risperidone without any clinically significant side effects.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	Trial of, contraindication to, or medical reason (e.g. intolerance, hypersensitivity or contraindication) for not using at least two of the following: Abilify Maintena, Abilify Asimtufii, Risperidone Microsphere, Invega Sustenna, Invega Trinza, and Invega Hafyera.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

RYLAZE

Products Affected

- RYLAZE

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	Prescriber must be an oncologist, hematologist, or specialist for submitted diagnosis.
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

SAPROPTERIN

Products Affected

- *sapropterin dihydrochloride oral packet*
- *sapropterin dihydrochloride oral tablet*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Phenylketonuria (PKU) - Initial: (1) patient has documented diagnosis of PKU and (2) patient has pretreatment phenylalanine level greater than 6 mg/dL or 360 micromol/L (note: pretreatment includes prior to dietary management). Continuation of therapy: patient has documented positive clinical response to treatment (i.e. improvement in neuropsychiatric symptoms or reduction in blood phenylalanine levels).
Age Restrictions	N/A
Prescriber Restrictions	Initial therapy only: prescribed by or in consultation with a specialist who focuses in the treatment of metabolic diseases.
Coverage Duration	Initial: 12 weeks. Continuation of therapy: end of contract year.
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

SECUADO

Products Affected

- SECUADO

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	(1) patient has been diagnosed with schizophrenia AND (2) patient has tried, intolerant or has medical reason for not using at least two generic antipsychotics (i.e. aripiprazole, olanzapine, risperidone, etc.).
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

SEROSTIM

Products Affected

- SEROSTIM SUBCUTANEOUS
SOLUTION RECONSTITUTED 4 MG, 5
MG, 6 MG

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off-Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

SIGNIFOR

Products Affected

- SIGNIFOR

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off-Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	No

SILDENAFIL ORAL

Products Affected

- *sildenafil citrate oral suspension reconstituted*
- *sildenafil citrate oral tablet 20 mg*

PA Criteria	Criteria Details
Exclusion Criteria	Documentation of concurrent nitrate or Adempas use.
Required Medical Information	Pulmonary arterial hypertension (PAH) - Initial: [Note: documentation required] (1) diagnosis confirmed by right heart catheterization AND (2) pretreatment mean pulmonary arterial pressure is greater than 20 mmHg AND (3) pretreatment pulmonary capillary wedge pressure is less than or equal to 15 mmHg AND (4) pretreatment pulmonary vascular resistance is greater than or equal to 3 Wood units AND (5) documentation of diagnosis via chart notes. Continuation of therapy: patient has positive clinical response to treatment. Secondary Raynaud's phenomenon - Initial: [Note: documentation required] (1) diagnosis of secondary Raynaud's phenomenon AND (2) diagnosis of primary condition which Raynaud's phenomenon is secondary to (e.g., lupus, scleroderma, rheumatoid arthritis, Sjogren's syndrome, thyroid disease). Continuation of therapy: patient has positive clinical response to treatment.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a cardiologist, pulmonologist, or a rheumatologist.
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	For sildenafil suspension: Documentation of trial of, contraindication to, or medical reason for not using sildenafil tablet.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Formulary ID 26323
Last Updated: 10/15/2025

SILIQ

Products Affected

- SILIQ

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with specialist for submitted diagnosis.
Coverage Duration	New starts will be authorized for 4 months. Cont of therapy or reauth until end of contract year.
Other Criteria	Psoriasis - Initial: trial of, medical reason for not using, or contraindication to 2 of the following therapies: an ustekinumab product, Tremfya, Enbrel or an adalimumab product. Continuation of therapy: patient has been receiving Siliq for a minimum of 4 months and has positive response to treatment.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

SIMPONI

Products Affected

- SIMPONI SUBCUTANEOUS SOLUTION AUTO-INJECTOR 100 MG/ML, 50 MG/0.5ML
- SIMPONI SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 100 MG/ML, 50 MG/0.5ML

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	Specialist for submitted diagnosis.
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	For ankylosing spondylitis: Either 1) Trial of, medical reason for not using, or contraindication to 2 of the following therapies: Enbrel, Cosentyx, an adalimumab product or Xeljanz, or 2) If utilized within the past 120 days, approve for continuation of therapy. For PsA: Either 1) Trial of, medical reason for not using, or contraindication to 2 of the following therapies: an ustekinumab product, Tremfya, Xeljanz, Enbrel, or an adalimumab product, or 2) If utilized within the past 120 days, approve for continuation of therapy. For RA: Either 1) Trial of, medical reason for not using, or contraindication to 2 of the following: Enbrel, an adalimumab product, or Xeljanz or 2) If utilized within the past 120 days, approve for continuation of therapy. For UC: Either 1) Trial of, medical reason for not using, or contraindication to 2 of the following: an adalimumab product, an ustekinumab product, Tremfya, or Xeljanz or 2) If utilized within the past 120 days, approve for continuation of therapy.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Formulary ID 26323
Last Updated: 10/15/2025

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

SIRTURO

Products Affected

- SIRTURO

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off-Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	No

SODIUM OXYBATE

Products Affected

- sodium oxybate*

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off-Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

SODIUM PHENYLBUTYRATE

Products Affected

- *sodium phenylbutyrate oral powder 3 gm/tsp*
- *sodium phenylbutyrate oral tablet*

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off-Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	No

SOFOSBUVIR/VELPATASVIR

Products Affected

- *sofosbuvir-velpatasvir*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Detectable HCV RNA viral load prior to treatment within 6 months of request. In addition, documentation of treatment history, and if cirrhotic, documentation of compensated or decompensated cirrhosis.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Request will be authorized for 12-24 weeks based on AASLD-IDSA guidelines
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

SOMAVERT

Products Affected

- SOMAVERT

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	For new starts for acromegaly: pt meets one of the following (1) inadequate response to surgery and/or radiotherapy OR (2) pt is not an appropriate candidate for surgery and/or radiotherapy OR (3) pt is experiencing negative effects due to tumor size (ex: optic nerve compression). Continuation of therapy or reauthorization: documentation of clinical improvement with therapy.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an endocrinologist.
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	Acromegaly: (1) patient has had an inadequate response to radiotherapy and/or surgery OR (2) patient is not a candidate for radiotherapy and/or surgery OR (3) patient is experiencing negative effects from tumor (i.e. optic nerve compression) AND (4) patient documented baseline (prior to treatment) insulin-like growth factor-1 (IGF-1) level is above the upper limit of normal (ULN) based on the age and gender for the reporting laboratory.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

SOTYKTU

Products Affected

- SOTYKTU

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with specialist for submitted diagnosis.
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	Moderate to severe Psoriasis - Initial: (1) patient has psoriasis affecting 3% or greater surface area involvement OR (2) psoriasis in sensitive areas such as face, groin, palms, soles of feet or scalp AND (2) patient has history of failure or medical reason for not using at least one conventional topical therapy (i.e. calcineurin inhibitors, corticosteroids, tazarotene or vitamin D analogs) AND (3) patient has history of failure or medical reason for not using at least one of the following products: an adalimumab product, Enbrel, Tremfya or an ustekinumab product. Continuation of therapy: patient has been receiving Sotyktu for a minimum of 4 months and has positive clinical response to therapy.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

SUCRAID

Products Affected

- SUCRAID

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	(1) Patient has symptomatic congenital sucrose-isomaltase deficiency (i.e. abdominal cramping, bloating, diarrhea) AND (2) documented diagnosis is established by one of the following: (i) molecular genetic testing demonstrating homozygous or compound heterozygous pathogenic or likely pathogenic sucrose isomaltase gene variant OR (ii) patient has endoscopic biopsy of the small bowel with disaccharidase levels consistent with congenital sucrose-isomaltase deficiency as evidenced by all of the following: (a) decreased normal isomaltase (palatinase) [normal reference: greater than 5 U/g protein] AND (b) decreased normal lactase (normal reference: greater than 15 U/g protein) AND (c) decreased maltase (normal reference: greater than 100 U/g protein) AND (d) decreased (typically absent) sucrose (normal reference: greater than 25 U/g protein).
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a gastroenterologist, geneticist, metabolic disorder specialist, or a provider who specializes in the treatment of congenital diarrheal disorders.
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

SYMDEKO

Products Affected

- SYMDEKO

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent use with Kalydeco, Orkambi or Trikafta. Patients with unknown CFTR gene mutations.
Required Medical Information	Documentation of CFTR gene that is responsive to tezacaftor-ivacaftor treatment.
Age Restrictions	6 years of age or older.
Prescriber Restrictions	Prescribed by or in consultation with a pulmonologist or a provider who specializes in CF.
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	Cystic Fibrosis (CF): patient must be homozygous for the F508del mutation or have at least one mutation in the CFTR gene that is responsive to the requested medication.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

SYNAREL

Products Affected

- SYNAREL

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	Endometriosis - Initial: (1) patient has been diagnosed with endometriosis AND (2) patient has tried, intolerant or has medical reason for not using two of the following: (i) oral contraceptive, (ii) oral or injectable depot medroxyprogesterone, or (iii) analgesic pain reliever (i.e. NSAIDs). Continuation of therapy: patient has positive clinical response to treatment.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

TADALAFIL

Products Affected

- *tadalafil (pah)*
- TADLIQ

PA Criteria	Criteria Details
Exclusion Criteria	Documentation of concurrent nitrate or Adempas use.
Required Medical Information	Pulmonary arterial hypertension (PAH) - Initial: [Note: documentation required] (1) diagnosis confirmed by right heart catheterization AND (2) pretreatment mean pulmonary arterial pressure is greater than 20 mmHg AND (3) pretreatment pulmonary capillary wedge pressure is less than or equal to 15 mmHg AND (4) pretreatment pulmonary vascular resistance is greater than 2 Wood units AND (5) documentation of diagnosis via chart notes. Continuation of therapy: patient has positive clinical response to treatment.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a cardiologist or a pulmonologist.
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	For Tadliq: Documentation of trial of, contraindication to, or medical reason for not using tadalafil tablets.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

TADALAFIL, BPH

Products Affected

- *tadalafil oral tablet 5 mg*

PA Criteria	Criteria Details
Exclusion Criteria	Diagnosis of erectile dysfunction
Required Medical Information	Diagnosis of Benign prostatic hyperplasia (BPH) required AND trial of, contraindication to, or medical reason for not using an alpha blocker (e.g. tamsulosin, terazosin).
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

TALTZ

Products Affected

- TALTZ SUBCUTANEOUS SOLUTION AUTO-INJECTOR
- TALTZ SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 20 MG/0.25ML, 40 MG/0.5ML, 80 MG/ML

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with specialist for submitted diagnosis.
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	For ankylosing spondylitis: Either 1) Trial of, medical reason for not using, or contraindication to 2 of the following therapies: Enbrel, Cosentyx, an adalimumab product, or Xeljanz, or 2) If utilized within the past 120 days, approve for continuation of therapy. For non-radiographic axial spondyloarthritis: Trial of, medical reason for not using, or contraindication to Cosentyx. For psoriasis: Either 1) Trial of, medical reason for not using, or contraindication (e.g., safety concerns, not indicated for patient's age) to 2 of the following therapies: an ustekinumab product, Tremfya, Enbrel, or an adalimumab product, or 2) If utilized within the past 120 days, approve for continuation of therapy. For PsA: Either 1) Trial of, medical reason for not using, or contraindication to 2 of the following therapies: an ustekinumab product, Tremfya, Xeljanz, Enbrel, or an adalimumab product, or 2) If utilized within the past 120 days, approve for continuation of therapy.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Formulary ID 26323

Last Updated: 10/15/2025

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

TARPEYO

Products Affected

- TARPEYO

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off-Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

TASIMELTEON

Products Affected

- HETLIOZ LQ
- tasimelteon*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with sleep specialist or neurologist.
Coverage Duration	Initial: 6 months. Continuation of therapy: end of contract year.
Other Criteria	Nighttime sleep disturbances in Smith Magenis Syndrome (SMS) - Initial: confirmation of diagnosis. Continuation of therapy: patient has positive clinical response to treatment. Non-24-Hour Sleep Wake Disorder - Initial: patient has diagnosis of total blindness in both eyes AND inability to perceive light in either eye. Continuation of therapy: patient experiences increase in total nighttime sleep OR decreased daytime nap duration.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

TAVNEOS

Products Affected

- TAVNEOS

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Initial: [Note: documentation required] (1) diagnosis of severe active anti-neutrophil cytoplasmic autoantibody (ANCA) associated vasculitis AND (2) documentation of diagnosis with one of the following types: (i) granulomatosis with polyangiitis (GPA) or (ii) microscopic polyangiitis (MPA) AND (3) Tavneos is being prescribed as part of adjunctive treatment used concurrently with standard therapy (i.e. azathioprine, cyclophosphamide, methotrexate, etc.) AND (4) patient is being treated with an initial immunosuppressive regimen to induce remission (i.e. cyclophosphamide, rituximab). Continuation of therapy: (1) patient does not show evidence of disease progression AND (2) Tavneos is being prescribed as part of adjunctive treatment used concurrently with standard therapy (defined above).
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a hematologist, nephrologist, pulmonologist, rheumatologist or vascular medicine specialist.
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	For new starts: 1) Prescriber attests that Tavneos will be prescribed in combination with corticosteroids AND cyclophosphamide unless there is documented trial of, contraindication to, or medical reason for not using these therapies. 2) Documentation of baseline Birmingham Vasculitis Activity Score (BVAS) score 3) Prescriber attestation that the patient will have liver function tests before treatment (ALT, AST, alkaline phosphate, and total bilirubin) and every 4 weeks after start of therapy for the first 6 months of treatment 4) Prescriber attestation that the patient has been screened for and does not have active hepatitis B virus (HBV) infection at baseline. For continuation of therapy or reauthorization: 1) Documentation of remission (BVAS score of 0) OR improvement in BVAS score 2) Prescriber attestation that patient has no abnormality in liver function tests (abnormality: ALT or AST greater than 3 times the upper limit of normal

PA Criteria	Criteria Details
	and bilirubin greater than 2 times the upper limit of normal) 3) Prescriber attestation that patient has no active HBV infection.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

TEPEZZA

Products Affected

- TEPEZZA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Documentation of moderate to severe active thyroid eye disease (TED) as evidenced by one or more of the following: a) eyelid retraction greater than or equal to 2 mm, b) moderate or severe soft tissue involvement, c) exophthalmos greater than or equal to 3 mm above normal for race and sex or d) periodic or constant diplopia OR Documentation of chronic TED with one or more of the following: a) a 3 mm or greater increase in exophthalmos from before diagnosis of TED, b) exophthalmos greater than or equal to 3 mm above normal for race and sex.
Age Restrictions	N/A
Prescriber Restrictions	Prescriber must be an ophthalmologist or endocrinologist
Coverage Duration	Request will be authorized for 6 months.
Other Criteria	For active TED: member has had a trial and failure, contraindication to, or medical reason for not using oral or IV glucocorticoids.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

TERIPARATIDE

Products Affected

- BONSITY
- *teriparatide subcutaneous solution pen-injector 560 mcg/2.24ml*

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off-Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

TESTOSTERONE CYPIONATE

Products Affected

- *testosterone cypionate intramuscular solution 100 mg/ml, 200 mg/ml, 200 mg/ml (1 ml)*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	Primary hypogonadism or hypogonadotropic hypogonadism - Initial: patient has at least two confirmed low morning serum total testosterone concentrations based on the reference laboratory range or current practice guidelines. Continuation of therapy: patient had a confirmed low morning serum total testosterone concentration based on the reference laboratory range or current practice guidelines before starting testosterone therapy. Gender dysphoria - Initial: the patient is able to make an informed decision to engage in hormone therapy. Continuation of therapy: approve.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

TESTOSTERONE ENANTHATE

Products Affected

- *testosterone enanthate intramuscular solution*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	Primary hypogonadism or hypogonadotropic hypogonadism - Initial: patient has at least two confirmed low morning serum total testosterone concentrations based on the reference laboratory range or current practice guidelines. Continuation of therapy: patient had a confirmed low morning serum total testosterone concentration based on the reference laboratory range or current practice guidelines before starting testosterone therapy. Gender dysphoria - Initial: the patient is able to make an informed decision to engage in hormone therapy. Continuation of therapy: approve.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

THIOLA

Products Affected

- *tiopronin oral*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	(1) Patient has diagnosis of cystinuria AND (2) diagnosis confirmed by laboratory testing (i.e. quantitative urine cystine assay, urinary cystine crystals present on microscopy) AND (3) patient weight at least 20 kilograms AND (4) prescriber attestation that patient has had inadequate response to dietary modifications, high fluid intake, and urinary alkalization. Continuation of therapy: patient has positive clinical response to treatment.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with nephrologist, urologist or provider specializing in treatment of cystinuria.
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

TIGECYCLINE

Products Affected

- *tigecycline*

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off-Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

TOBI PODHALER

Products Affected

- TOBI PODHALER

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Patient has documented diagnosis of both: 1) cystic fibrosis AND 2) pseudomonas aeruginosa
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with pulmonologist, infectious disease specialist, or a provider who specializes in treatment of CF.
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

TOLVAPTAN

Products Affected

- *tolvaptan (hyponatremia)*
- *tolvaptan oral tablet 15 mg, 30 mg*
- *tolvaptan oral tablet therapy pack*

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off-Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	No

TOPICAL ANTINEOPLASTIC RETINOIDS

Products Affected

- *bexarotene*
- PANRETIN

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a dermatologist, oncologist or specialist for submitted diagnosis
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

TOPICAL TESTOSTERONE

Products Affected

- testosterone transdermal gel 1.62 %, 12.5 mg/act (1%), 20.25 mg/1.25gm (1.62%), 20.25 mg/act (1.62%), 25 mg/2.5gm (1%), 40.5 mg/2.5gm (1.62%), 50 mg/5gm (1%)
- testosterone transdermal solution

PA Criteria	Criteria Details
Exclusion Criteria	Patient has history of prostate cancer or breast cancer.
Required Medical Information	New starts of topical testosterone therapy for hypogonadism must have both of the following characteristics of hypogonadism: 1) symptoms associated with hypogonadism (e.g. unexplained mild anemia, low libido, decreased energy, etc.) 2) Two separate instances of low serum total or free testosterone taken in the morning, as defined by the lab reference range.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	Primary hypogonadism or hypogonadotropic hypogonadism - Initial: patient has at least two confirmed low morning serum total testosterone concentrations based on the reference laboratory range or current practice guidelines. Continuation of therapy: patient had a confirmed low morning serum total testosterone concentration based on the reference laboratory range or current practice guidelines before starting testosterone therapy. Gender dysphoria - Initial: the patient is able to make an informed decision to engage in hormone therapy. Continuation of therapy: approve.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

TRANSDERMAL LIDOCAINE

Products Affected

- *lidocaine external patch 5 %*
- ZTLIDO

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Documented diagnosis of a medically-accepted indication.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	If the request is for the product ZTlido, must provide medical reason for not being able to use generic lidocaine 5% patch
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

TREMFYA

Products Affected

- TREMFYA CROHNS INDUCTION
- TREMFYA ONE-PRESS SUBCUTANEOUS SOLUTION PEN-INJECTOR
- TREMFYA PEN SUBCUTANEOUS SOLUTION AUTO-INJECTOR 100 MG/ML, 200 MG/2ML
- TREMFYA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 100 MG/ML, 200 MG/2ML
- TREMFYA-CD/UC INDUCTION

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off-Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

TRIENTINE

Products Affected

- CUVRIOR
- *trientine hcl oral capsule 250 mg*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a gastroenterologist, hepatologist, or liver transplant specialist.
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	Wilson's Disease - Initial: (1) diagnosis of Wilson's disease is confirmed by genetic testing results confirming biallelic pathogenic ATP7B mutations (in either symptomatic or asymptomatic individuals) OR confirmation of at least two of the following (i, ii, iii, and/or iv): (i) 24-hour urinary copper greater than 40 micrograms/24 hours OR (ii) liver biopsy findings consistent with Wilson's disease OR (iii) presence of Kayser Fleischer rings OR iv) serum ceruloplasmin levels less than 20mg/dL AND (2) patient has tried, intolerance to (i.e. autoimmune tendency, congestive splenomegaly causing severe thrombocytopenia, history of any renal disease) or has medical reason for not using penicillamine therapy OR (3) patient has neurologic manifestations of Wilson's disease OR (4) patient is pregnant. Continuation of therapy: approve.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Formulary ID 26323

Last Updated: 10/15/2025

TRIKAFTA

Products Affected

- TRIKAFTA ORAL TABLET THERAPY
- TRIKAFTA ORAL THERAPY PACK PACK

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent use with Kalydeco, Orkambi, or Symdeko. Patients with unknown CFTR gene mutations.
Required Medical Information	Documentation of CFTR gene that is responsive to elexacaftor-tezacaftor-ivacaftor treatment.
Age Restrictions	2 years of age or older.
Prescriber Restrictions	Prescribed by or in consultation with a pulmonologist or a provider who specializes in treatment of CF.
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	Cystic Fibrosis (CF) - Initial: patient must have at least one F508del mutation in the CFTR gene or a mutation in the CFTR gene that is responsive to the requested medication. Continuation of therapy: approve.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

TYMLOS

Products Affected

- TYMLOS

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off-Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

TYVASO

Products Affected

- TYVASO DPI MAINTENANCE KIT
INHALATION POWDER 16 MCG, 32 MCG, 48 MCG, 64 MCG
- TYVASO DPI TITRATION KIT
INHALATION POWDER 16 & 32 & 48 MCG

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Pulmonary arterial hypertension (PAH) - Initial: [Note: documentation required] (1) diagnosis confirmed by right heart catheterization AND (2) pretreatment mean pulmonary arterial pressure is greater than 20 mmHg AND (3) pretreatment pulmonary capillary wedge pressure is less than or equal to 15 mmHg AND (4) pretreatment pulmonary vascular resistance is greater than or equal to 3 Wood units. Continuation of therapy: patient has positive clinical response to treatment. Pulmonary hypertension associated with interstitial lung disease (PH-ILD, WHO Group 3) - Initial [Note: documentation required] (1) documented diagnosis of PH-ILD, WHO Group 3 confirmed by right heart catheterization AND (2) patient has connective tissue disease with baseline forced vital capacity less than 70% AND (3) patient has evidence of diffuse parenchymal lung disease on computed tomography of the chest. Continuation of therapy: patient has positive clinical response to treatment.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a cardiologist or a pulmonologist.
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	For the treatment of pulmonary arterial hypertension (PAH): 1) documentation of PAH WHO Group I classification and PAH Functional Class and 2) trial of, contraindication to, or medical reason for not using a generic phosphodiesterase inhibitor and a generic endothelin receptor antagonist. For the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD, WHO Group 3): documentation of PH-ILD and PAH Functional Class.
Indications	All Medically-accepted Indications.

PA Criteria	Criteria Details
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

UBRELVY

Products Affected

- UBRELVY

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Acute treatment of migraine - Initial: patient has tried and failed, intolerant or has medical reason for not using at least one triptan 5-HT1 receptor agonist. Continuation of therapy: must show documentation of improvement in migraine symptoms (pain, photophobia, phonophobia).
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Initial: 6 months. Continuation of therapy: end of contract year.
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

UPTRAVI

Products Affected

- UPTRAVI ORAL
- UPTRAVI TITRATION

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Pulmonary arterial hypertension (PAH) - Initial: [Note: documentation required] (1) diagnosis confirmed by right heart catheterization AND (2) pretreatment mean pulmonary arterial pressure is greater than 20 mmHg AND (3) pretreatment pulmonary capillary wedge pressure is less than or equal to 15 mmHg AND (4) pretreatment pulmonary vascular resistance is greater than or equal to 3 Wood units. Continuation of therapy: patient has positive clinical response to treatment.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a cardiologist or a pulmonologist.
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	Trial of, contraindication to, or medical reason for not using a generic phosphodiesterase inhibitor and a generic endothelin receptor antagonist.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

USTEKINUMAB

Products Affected

- IMULDOSA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 45 MG/0.5ML, 90 MG/ML
- SELARSDI INTRAVENOUS
- SELARSDI SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 45 MG/0.5ML, 90 MG/ML
- STELARA INTRAVENOUS
- STELARA SUBCUTANEOUS SOLUTION 45 MG/0.5ML
- STELARA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 45 MG/0.5ML, 90 MG/ML
- STEQEYMA INTRAVENOUS
- STEQEYMA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 45 MG/0.5ML, 90 MG/ML
- *ustekinumab subcutaneous solution*
- *ustekinumab subcutaneous solution prefilled syringe 45 mg/0.5ml, 90 mg/ml*
- *ustekinumab-aekn subcutaneous solution prefilled syringe 45 mg/0.5ml, 90 mg/ml*
- YESINTEK INTRAVENOUS
- YESINTEK SUBCUTANEOUS SOLUTION
- YESINTEK SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 45 MG/0.5ML, 90 MG/ML

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off-Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

UZEDY

Products Affected

- | | |
|---|--|
| <ul style="list-style-type: none"> • UZEDY SUBCUTANEOUS
SUSPENSION PREFILLED SYRINGE
100 MG/0.28ML, 125 MG/0.35ML, 150 | MG/0.42ML, 200 MG/0.56ML, 250
MG/0.7ML, 50 MG/0.14ML, 75
MG/0.21ML |
|---|--|

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	The member has a documented history of receiving oral risperidone without any clinically significant side effects.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	Trial and failure of, contraindication, or medical reason for not using at least two of the following: Abilify Maintena, Abilify Asimtufii, Risperidone Microsphere, Invega Sustenna, Invega Trinza, and Invega Hafyera.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

VALCHLOR

Products Affected

- VALCHLOR

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or dermatologist.
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	Trial of, contraindication to, or medical reason for not being able to use one of the following: a topical corticosteroids or a topical retinoids.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

VEMLIDY

Products Affected

- VEMLIDY

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	For new starts: attestation that member has been tested for HIV infection. If member is HIV-positive, Vemlidy is not used alone.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

VEOZAH

Products Affected

- VEOZAH

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Initial: (1) Documented diagnosis of moderate to severe vasomotor symptoms due to menopause AND (2) Trial of, contraindication to, or medical reason (e.g. intolerance, hypersensitivity or contraindication) for not using a hormonal therapy (e.g., estradiol, oral Premarin, Prempro). Reauthorization: (1) Documentation of positive clinical response to therapy (e.g., decrease in frequency or severity of vasomotor symptoms from baseline)
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

VIGABATRIN

Products Affected

- *vigabatrin*
- VIGAFYDE

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	For diagnosis of refractory complex partial seizures - initial: 1) documentation of diagnosis, and 2) attestation the member is currently receiving another antiepileptic drug, and 3) attestation the member has experienced treatment failure from two generic alternative formulary antiepileptic agents. Continuation of therapy: patient has positive clinical response to treatment (i.e., reduced seizure severity, frequency, or duration). For diagnosis of infantile spasm - initial: requested medication is being used as monotherapy. Continuation of therapy: patient has positive clinical response to treatment.
Age Restrictions	Refractory complex partial seizures: 2 years of age or older. Infantile spasms: less than or equal to 2 years of age.
Prescriber Restrictions	Prescribed by or in consultation with a neurologist.
Coverage Duration	Initial- infantile spasms: 6 mos, refractory partial seizures: 3 mos. Cont-end of contract yr.
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

VIJOICE

Products Affected

- VIJOICE ORAL PACKET
- VIJOICE ORAL TABLET THERAPY
PACK 125 MG, 200 & 50 MG, 50 MG

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Initial: (1) documented diagnosis of PIK3CA-Related Overgrowth Spectrum (PROS) AND documentation of mutation in the PIK3CA gene AND (2) documentation of severe clinical manifestations AND (3) at least one target lesion identified on imaging. Continuation of therapy: documentation of positive clinical response to treatment.
Age Restrictions	2 years of age or older.
Prescriber Restrictions	Prescribed by or in consultation with a geneticist, dermatologist, vascular surgeon, hematologist/oncologist, or other specialist in the treatment of PIK3CA-Related Overgrowth Spectrum(PROS).
Coverage Duration	Initial: 6 months. Continuation of therapy: end of contract year.
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

VMAT-2 INHIBITORS

Products Affected

- AUSTEDO ORAL TABLET 12 MG, 6 MG, 9 MG
- AUSTEDO XR ORAL TABLET EXTENDED RELEASE 24 HOUR 12 MG, 18 MG, 24 MG, 30 MG, 36 MG, 42 MG, 48 MG, 6 MG
- AUSTEDO XR PATIENT TITRATION ORAL TABLET EXTENDED RELEASE
- THERAPY PACK 12 & 18 & 24 & 30 MG
- INGREZZA ORAL CAPSULE
- INGREZZA ORAL CAPSULE SPRINKLE
- INGREZZA ORAL CAPSULE THERAPY PACK
- *tetrabenazine*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

VOQUEZNA

Products Affected

- VOQUEZNA
- VOQUEZNA DUAL PAK
- VOQUEZNA TRIPLE PAK

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off-Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

VORICONAZOLE

Products Affected

- *voriconazole intravenous*
- *voriconazole oral*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Request will be authorized for 6 months.
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

VOSEVI

Products Affected

- VOSEVI

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Detectable HCV RNA viral load prior to treatment within 6 months of request. In addition, documentation of treatment history, and if cirrhotic, documentation of compensated or decompensated cirrhosis.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Request will be authorized for 12 weeks as per AASLD-IDSA guidance.
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

VOWST

Products Affected

- VOWST

PA Criteria	Criteria Details
Exclusion Criteria	Treatment of Clostridioides difficile infection (CDI)
Required Medical Information	Initial: (1) documented diagnosis of recurrent clostridioides difficile infection (CDI) AND (2) documentation patient has completed at least 10 consecutive days of CDI treatment antibiotic therapies 2-4 days prior to initiating therapy.
Age Restrictions	18 years of age or older.
Prescriber Restrictions	Prescribed by or in consultation with gastroenterologist or infections disease specialist.
Coverage Duration	Request will be authorized for 14 days
Other Criteria	Diagnosis of at least 1 recurrent episode of CDI
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

VYNDAMAX

Products Affected

- VYNDAMAX

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Member has documented diagnosis with transthyretin-mediated amyloidosis with cardiomyopathy (ATTR-CM) with documentation of one of the following: (1) Member has a transthyretin (TTR) mutation (e.g., V122I) OR (2) Cardiac or non-cardiac tissue biopsy demonstrating histologic confirmation of TTR amyloid deposits OR (3) all of the following: (a) echocardiogram or cardiac magnetic resonance image suggestive of amyloidosis, (b) scintigraphy scan suggestive of cardiac TTR amyloidosis, (c) absence of light-chain amyloidosis.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a cardiologist or prescriber specializing in treatment of amyloidosis.
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

WEGOVY

Products Affected

- WEGOVY SUBCUTANEOUS SOLUTION AUTO-INJECTOR 0.25 MG/0.5ML, 0.5 MG/0.5ML, 1 MG/0.5ML, 1.7 MG/0.75ML, 2.4 MG/0.75ML

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off-Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	No

WHITE BLOOD CELL STIMULATORS

Products Affected

- FULPHILA
- FYLNETRA
- LEUKINE INJECTION SOLUTION RECONSTITUTED
- NEULASTA ONPRO SUBCUTANEOUS SOLUTION PREFILLED SYRINGE
- NEULASTA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE
- ZARXIO

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Documentation of medically accepted indication.
Age Restrictions	N/A
Prescriber Restrictions	Specialist for submitted diagnosis.
Coverage Duration	New starts will be authorized for 4 months. Cont of therapy or reauth until end of contract year.
Other Criteria	Cancer patient undergoing chemotherapy: (1) patient is receiving myelosuppressive chemotherapy associated with high risk of febrile neutropenia OR (2) patient has one or more risk factors for febrile neutropenia as documented by the prescriber (i.e. 65 years of age or older, prior chemotherapy or radiation therapy, persistent neutropenia, recent surgery, liver and/or renal impairment, bone marrow involvement by tumor, poor performance status or HIV infection) OR (3) patient has had a neutropenic complication from prior chemotherapy and did not receive prophylaxis with a colony stimulating factor and a dose reduction or change in frequency of chemotherapy may compromise treatment. For new starts for Neulasta and Fylnetra: documentation of trial of, contraindication to, or medical reason for not using Fulphila. Continuation of therapy or re-authorization criteria: diagnosis of chronic neutropenia or a medical reason for continued need for GCSF.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

PA Criteria	Criteria Details
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

WINREVAIR

Products Affected

- WINREVAIR

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Pulmonary arterial hypertension (PAH) (World Health Organization [WHO] Group 1)- Initial: [Note: documentation required] (1) PAH was confirmed by right heart catheterization AND (2) pretreatment mean pulmonary arterial pressure is greater than 20 mmHg AND (3) pretreatment pulmonary capillary wedge pressure is less than or equal to 15 mmHg, AND (4) pretreatment pulmonary vascular resistance is greater than or equal to 3 Wood units. Continuation of therapy: patient has positive clinical response to treatment.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a cardiologist or pulmonologist.
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	Documented trial and failure of, or contraindication to combination therapy including one PDE-5 inhibitor AND one endothelin receptor antagonist. Documentation of platelet count of greater than 50,000/mm3.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

XDEMVY

Products Affected

- XDEMVY

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

XELJANZ

Products Affected

- XELJANZ ORAL SOLUTION
- XELJANZ ORAL TABLET
- XELJANZ XR

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off-Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

XERMELO

Products Affected

- XERMELO

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off-Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	No

XIAFLEX

Products Affected

- XIAFLEX

PA Criteria	Criteria Details
Exclusion Criteria	Peyronie's plaques that involve the penile urethra.
Required Medical Information	Dupuytren's Contracture: 1) Documented diagnosis of Dupuytren's Contracture with a palpable cord AND 2) Documentation that flexion deformity results in functional limitations AND 3) Documentation of which cords are being treated and dates of treatment. Peyronie's Disease: 1) Documented diagnosis of Peyronie's Disease with a palpable plaque AND 2) Documentation that prior to start of therapy curvature deformity is at least 30 degrees.
Age Restrictions	N/A
Prescriber Restrictions	Dupuytren's Contracture: Prescribed by or in consultation with an orthopedic surgeon or other orthopedic specialist. Peyronie's Disease: Prescribed by or in consultation with a urologist.
Coverage Duration	Dupuytren's Contracture: 3 months. Peyronie's Disease: 6 months.
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

XIFAXAN

Products Affected

- XIFAXAN ORAL TABLET 200 MG, 550 MG

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	For HE: gastroenterologist or hepatologist. For IBS-D: gastroenterologist.
Coverage Duration	HE: 6 mos. IBS-D: 14 days. Travelers' Diarrhea: 3 days.
Other Criteria	For irritable bowel syndrome with diarrhea (IBS-D): (1) patient has not previously received treatment with the requested drug OR (2) patient has previously received treatment with the requested drug AND (i) the patient is experiencing a recurrence of symptoms AND (ii) the patient has not already received an initial 14-day course of treatment and two additional 14-day courses of treatment with Xifaxan.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

XOLAIR

Products Affected

- XOLAIR

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off-Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

XOLREMDI

Products Affected

- XOLREMDI

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	Prescriber must be an immunologist, dermatologist, or a hematologist.
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	For new starts: 1) A diagnosis of WHIM (warts, hypogammaglobulinemia, infections and myelokathexis) syndrome confirmed by genotype variant of chemokine receptor 4 (CXCR4) and absolute neutrophil count (ANC) of less than or equal to 400 cells/microliter or white blood cells (WBC) less than or equal to 400 cells/microliter and 2) Documentation of baseline ANC and absolute lymphocyte count (ALC). For renewal 1) Documentation or provider attestation of positive clinical response (i.e. improvement from baseline in ANC, WBC and/or ALC or reduced frequency, duration, or severity of infections, fewer warts, or improved or stabilized clinical signs and/or symptoms of WHIM).
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

XYWAV

Products Affected

- XYWAV

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	For use for narcolepsy with cataplexy - Initial: documented diagnosis of narcolepsy with cataplexy. Continuation of therapy: documentation of clinical response, reduction in frequency of cataplexy attacks associated. For use for narcolepsy with excessive daytime sleepiness: (1) patient has a documented diagnosis of narcolepsy according to ICSD-3 or DSM-5 criteria AND (2) patient has condition of excessive daytime sleepiness (EDS) associated with narcolepsy as confirmed AND (3) previous treatment, intolerance, or contraindication to at least one CNS stimulant or modafinil or armodafinil. Continuation of therapy: documentation demonstrating a reduction in symptoms of EDS.
Age Restrictions	N/A
Prescriber Restrictions	Prescriber must be a sleep specialist, pulmonologist or a neurologist.
Coverage Duration	Initial authorization: 3 months. Reauthorization: 6 months.
Other Criteria	For treatment of somnolence associated with narcolepsy, patient must have documentation of either trial of or a medical reason for being unable to use a CNS stimulant (e.g. methylphenidate, modafinil, armodafinil, etc.). For the treatment of cataplexy associated with narcolepsy or idiopathic hypersomnia, approve.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

YORVIPATH

Products Affected

- YORVIPATH

PA Criteria	Criteria Details
Exclusion Criteria	Diagnosis of acute post-surgical hypoparathyroidism.
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an endocrinologist.
Coverage Duration	New starts will be authorized for 6 months. Cont of therapy or reauth until end of contract year.
Other Criteria	For new starts: 1) Documented diagnosis of chronic hypoparathyroidism AND 2) Provider attestation that patient is currently receiving or has medical reason for not receiving calcium supplementation and active vitamin D treatment AND 3) An albumin-corrected serum calcium level of 7.8 mg/dL or greater. For reauthorization: Documentation of improvement in albumin-corrected serum calcium from baseline.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

YUTREPIA

Products Affected

- YUTREPIA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a cardiologist or a pulmonologist.
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	Pulmonary arterial hypertension (PAH) - Initial: [Note: documentation required] (1) diagnosis confirmed by right heart catheterization AND (2) pretreatment mean pulmonary arterial pressure is greater than 20 mmHg AND (3) pretreatment pulmonary capillary wedge pressure is less than or equal to 15 mmHg AND (4) pretreatment pulmonary vascular resistance is greater than or equal to 3 Wood units AND (5) documentation of PAH WHO Group I classification and PAH Functional Class AND (6) trial of, contraindication to, or medical reason for not using a generic phosphodiesterase inhibitor and a generic endothelin receptor antagonist. Continuation of therapy: patient has positive clinical response to treatment. Pulmonary hypertension associated with interstitial lung disease (PH-ILD, WHO Group 3) - Initial [Note: documentation required] (1) documented diagnosis of PH-ILD, WHO Group 3 confirmed by right heart catheterization AND (2) patient has connective tissue disease with baseline forced vital capacity less than 70% AND (3) patient has evidence of diffuse parenchymal lung disease on computed tomography of the chest AND (4) documentation of PAH functional class. Continuation of therapy: patient has positive clinical response to treatment.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

PA Criteria	Criteria Details
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

ZAVZPRET

Products Affected

- ZAVZPRET

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Acute treatment of migraine - Initial: (1) patient has tried and failed, intolerant or has medical reason for not using at least one triptan 5-HT ₁ receptor agonist AND Ubrelvy AND Nurtec . Continuation of therapy: must show documentation of improvement in migraine symptoms (pain, photophobia, phonophobia).
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Initial: 6 months. Continuation of therapy: end of contract year.
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

ZEPBOUND

Products Affected

- ZEPBOUND SUBCUTANEOUS SOLUTION AUTO-INJECTOR

PA Criteria	Criteria Details
Exclusion Criteria	The member has an indication of only weight reduction or maintenance for overweight or obesity. The member has concurrent use of any GLP-1 receptor agonist. The member has a personal history of medullary thyroid carcinoma. The member has Multiple Endocrine Neoplasia syndrome type 2.
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a sleep disorder specialist, pulmonologist, ENT, or other provider specializing in obstructive sleep apnea.
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	For new starts: The member has an indication for moderate to severe obstructive sleep apnea (OSA) in adults with obesity. Documentation of diagnosis of OSA through polysomnography (sleep study) with an apnea-hypopnea index of 15 or more events per hour, or five or more events per hour in the presence of symptoms (e.g., cognitive impairment, fatigue, insomnia, loud snoring) or cardiovascular comorbidities (e.g., hypertension, ischemic heart disease, previous stroke). Documentation is provided that the patient is obese (defined as a BMI of greater than or equal to 30 kg/m ²). For continuation of therapy: Documentation of positive response to treatment. Documentation member has achieved and/or maintained a decrease in weight since baseline.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Formulary ID 26323

Last Updated: 10/15/2025

PA Criteria	Criteria Details
Prerequisite Therapy Required	No

ZEPOSIA

Products Affected

- ZEPOSIA
- ZEPOSIA 7-DAY STARTER PACK
- ZEPOSIA STARTER KIT ORAL CAPSULE THERAPY PACK 0.23MG & 0.46MG 0.92MG(21)

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	Specialist for submitted diagnosis.
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	For multiple sclerosis: Trial of, contraindication to, or medical reason for not using two of the following: dalfampridine ER, dimethyl fumarate, fingolimod, glatiramer, glatopa, or teriflunomide. For ulcerative colitis: Either 1) Trial of, medical reason for not using, or contraindication to 1 of the following: an ustekinumab product or an adalimumab product or 2) If utilized within the past 120 days, approve for continuation of therapy.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

ZILBRYSQ

Products Affected

- ZILBRYSQ SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 16.6 MG/0.416ML, 23 MG/0.574ML, 32.4 MG/0.81ML

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	Prescriber must be a neurologist, rheumatologist, or other appropriate specialist
Coverage Duration	Request will be authorized until the end of the contract year.
Other Criteria	Patient has tried and failed, a medical reason for not using, or has a contraindication to two (2) or more conventional therapies (i.e. pyridostigmine, corticosteroids, or non-steroidal immunosuppressive therapies)
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

ZTALMY

Products Affected

- ZTALMY

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off-Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

ZURZUVAE

Products Affected

- ZURZUVAE ORAL CAPSULE 20 MG, 25 MG, 30 MG

PA Criteria	Criteria Details
Exclusion Criteria	UNDER CMS REVIEW
Required Medical Information	UNDER CMS REVIEW
Age Restrictions	UNDER CMS REVIEW
Prescriber Restrictions	UNDER CMS REVIEW
Coverage Duration	UNDER CMS REVIEW
Other Criteria	UNDER CMS REVIEW
Indications	UNDER CMS REVIEW
Off-Label Uses	UNDER CMS REVIEW
Part B Prerequisite	No
Prerequisite Therapy Required	No

PART B VERSUS PART D

Products Affected

- *acetylcysteine inhalation solution 10 %, 20 %*
- *acyclovir sodium intravenous solution 50 mg/ml*
- *albuterol sulfate inhalation nebulization solution (2.5 mg/3ml) 0.083%, (5 mg/ml) 0.5%, 0.63 mg/3ml, 1.25 mg/3ml, 2.5 mg/0.5ml*
- *amphotericin b intravenous solution reconstituted 50 mg*
- *amphotericin b liposome intravenous suspension reconstituted 50 mg*
- *aprepitant oral capsule 125 mg, 40 mg, 80 & 125 mg, 80 mg*
- *ASTAGRAF XL ORAL CAPSULE EXTENDED RELEASE 24 HOUR 0.5 MG, 1 MG, 5 MG*
- *azathioprine oral tablet 50 mg*
- *budesonide inhalation suspension 0.25 mg/2ml, 0.5 mg/2ml, 1 mg/2ml*
- *calcium acetate (phos binder) oral capsule 667 mg*
- *calcium acetate (phos binder) oral tablet 667 mg*
- *CLINISOL SF INTRAVENOUS SOLUTION 15 %*
- *cromolyn sodium inhalation nebulization solution 20 mg/2ml*
- *cyclophosphamide oral capsule 25 mg, 50 mg*
- *cyclophosphamide oral tablet 25 mg, 50 mg*
- *cyclosporine modified oral capsule 100 mg, 25 mg, 50 mg*
- *cyclosporine modified oral solution 100 mg/ml*
- *cyclosporine oral capsule 100 mg, 25 mg*
- *dronabinol oral capsule 10 mg, 2.5 mg, 5 mg*
- *EMEND ORAL SUSPENSION RECONSTITUTED 125 MG/5ML*
- *ENGRIX-B INJECTION SUSPENSION 20 MCG/ML*
- *ENGRIX-B INJECTION SUSPENSION PREFILLED SYRINGE 10 MCG/0.5ML, 20 MCG/ML*
- *ENVARBUS XR ORAL TABLET EXTENDED RELEASE 24 HOUR 0.75 MG, 1 MG, 4 MG*
- *everolimus oral tablet 0.25 mg, 0.5 mg, 0.75 mg, 1 mg*
- *formoterol fumarate inhalation nebulization solution 20 mcg/2ml*
- *GAMMAGARD INJECTION SOLUTION 1 GM/10ML, 10 GM/100ML, 2.5 GM/25ML, 20 GM/200ML, 30 GM/300ML, 5 GM/50ML*
- *GAMMAGARD S/D LESS IGA INTRAVENOUS SOLUTION RECONSTITUTED 10 GM, 5 GM*
- *GAMMAKED INJECTION SOLUTION 1 GM/10ML*
- *GAMMAPLEX INTRAVENOUS SOLUTION 10 GM/100ML, 10 GM/200ML, 20 GM/200ML, 5 GM/50ML*
- *GAMUNEX-C INJECTION SOLUTION 1 GM/10ML*
- *GENGRAF ORAL CAPSULE 100 MG, 25 MG*
- *granisetron hcl oral tablet 1 mg*
- *HEPLISAV-B INTRAMUSCULAR SOLUTION PREFILLED SYRINGE 20 MCG/0.5ML*
- *IMOVAX RABIES INTRAMUSCULAR SUSPENSION RECONSTITUTED 2.5 UNIT/ML*
- *INTRALIPID INTRAVENOUS EMULSION 20 %, 30 %*
- *ipratropium bromide inhalation solution 0.02 %*
- *ipratropium-albuterol inhalation solution 0.5-2.5 (3) mg/3ml*

- *lanthanum carbonate oral tablet chewable 1000 mg, 500 mg, 750 mg*
- *levalbuterol hcl inhalation nebulization solution 0.31 mg/3ml, 0.63 mg/3ml, 1.25 mg/3ml*
- *mycophenolate mofetil oral capsule 250 mg*
- *mycophenolate mofetil oral suspension reconstituted 200 mg/ml*
- *mycophenolate mofetil oral tablet 500 mg*
- *mycophenolate sodium oral tablet delayed release 180 mg, 360 mg*
- NUTRILIPID INTRAVENOUS EMULSION 20 %
- *ondansetron hcl oral solution 4 mg/5ml*
- *ondansetron hcl oral tablet 24 mg, 4 mg, 8 mg*
- *ondansetron oral tablet dispersible 4 mg, 8 mg*
- *pentamidine isethionate inhalation solution reconstituted 300 mg*
- PLENAMINE INTRAVENOUS SOLUTION 15 %
- PREHEVBRIO INTRAMUSCULAR SUSPENSION 10 MCG/ML
- PRIVIGEN INTRAVENOUS SOLUTION 10 GM/100ML, 20 GM/200ML, 40 GM/400ML, 5 GM/50ML
- PROGRAF INTRAVENOUS SOLUTION 5 MG/ML
- PROGRAF ORAL PACKET 0.2 MG, 1 MG
- PULMOZYME INHALATION SOLUTION 2.5 MG/2.5ML
- RABAVERT INTRAMUSCULAR SUSPENSION RECONSTITUTED
- RECOMBIVAX HB INJECTION SUSPENSION 10 MCG/ML, 40 MCG/ML, 5 MCG/0.5ML
- RECOMBIVAX HB INJECTION SUSPENSION PREFILLED SYRINGE 10 MCG/ML, 5 MCG/0.5ML
- *sevelamer carbonate oral packet 0.8 gm, 2.4 gm*
- *sevelamer carbonate oral tablet 800 mg*
- *sirolimus oral solution 1 mg/ml*
- *sirolimus oral tablet 0.5 mg, 1 mg, 2 mg*
- *tacrolimus oral capsule 0.5 mg, 1 mg, 5 mg*
- TENIVAC INTRAMUSCULAR INJECTABLE 5-2 LFU, 5-2 LFU (INJECTION)
- TENIVAC INTRAMUSCULAR SUSPENSION 5-2 LF/0.5ML
- *tobramycin inhalation nebulization solution 300 mg/4ml, 300 mg/5ml*

Details

This drug may be covered under Medicare Part B or D depending upon the circumstances. Information may need to be submitted describing the use and setting of the drug to make the determination.

Index

A

abiraterone acetate oral tablet 250 mg, 500 mg 12, 14
 ABIRTEGA 12, 14
 acetylcysteine inhalation solution 10 %, 20 % 257
 acitretin 1
 ACTEMRA ACTPEN 4
 ACTEMRA SUBCUTANEOUS 4
 ACTIMMUNE 5
 acyclovir sodium intravenous solution 50 mg/ml 257
 adalimumab-fkjp (2 pen)..... 6
 adalimumab-fkjp (2 syringe) subcutaneous prefilled syringe kit 20 mg/0.4ml, 40 mg/0.8ml 6
 ADEMPAS 7
 AIMOVIG 8
 AKEEGA 12, 14
 albuterol sulfate inhalation nebulization solution (2.5 mg/3ml) 0.083%, (5 mg/ml) 0.5%, 0.63 mg/3ml, 1.25 mg/3ml, 2.5 mg/0.5ml 257
 ALECENSA..... 12, 14
 ALUNBRIG ORAL TABLET 180 MG, 30 MG, 90 MG..... 12, 14
 ALUNBRIG ORAL TABLET THERAPY PACK..... 12, 14
 ALYFTREK ORAL TABLET 10-50-125 MG, 4-20-50 MG 10
 ambrisentan 11
 amitriptyline hcl oral..... 86
 amoxapine 86
 amphotericin b intravenous solution reconstituted 50 mg..... 257
 amphotericin b liposome intravenous suspension reconstituted 50 mg 257
 apomorphine hcl subcutaneous 15
 aprepitant oral capsule 125 mg, 40 mg, 80 & 125 mg, 80 mg 257
 AQNEURSA..... 16

ARALAST NP INTRAVENOUS SOLUTION RECONSTITUTED 1000 MG, 500 MG..... 9
 ARANESP (ALBUMIN FREE) INJECTION SOLUTION 100 MCG/ML, 200 MCG/ML, 25 MCG/ML, 40 MCG/ML, 60 MCG/ML 65
 ARANESP (ALBUMIN FREE) INJECTION SOLUTION PREFILLED SYRINGE 65
 ARCALYST 17, 18
 ARIKAYCE 19
 ARISTADA INITIO 20
 ARISTADA INTRAMUSCULAR PREFILLED SYRINGE 1064 MG/3.9ML, 441 MG/1.6ML, 662 MG/2.4ML, 882 MG/3.2ML 20
 armodafinil oral tablet 150 mg, 200 mg, 250 mg, 50 mg 126
 ASTAGRAF XL ORAL CAPSULE EXTENDED RELEASE 24 HOUR 0.5 MG, 1 MG, 5 MG 257
 AUGTYRO ORAL CAPSULE 160 MG, 40 MG 12, 14
 AUSTEDO ORAL TABLET 12 MG, 6 MG, 9 MG 229
 AUSTEDO XR ORAL TABLET EXTENDED RELEASE 24 HOUR 12 MG, 18 MG, 24 MG, 30 MG, 36 MG, 42 MG, 48 MG, 6 MG 229
 AUSTEDO XR PATIENT TITRATION ORAL TABLET EXTENDED RELEASE THERAPY PACK 12 & 18 & 24 & 30 MG 229
 AUVELITY 21
 AVMAPKI FAKZYNJA CO-PACK.. 12, 14
 AYVAKIT 12, 14
 azathioprine oral tablet 50 mg..... 257
B
 BAC (BUTALBITAL-ACETAMIN-CAFF) 88
 BAFIERTAM 121, 122
 BALVERSA 12, 14

BENLYSTA SUBCUTANEOUS..... 23, 24
 bexarotene 12, 14, 210
 BONSITY 203
 bosentan oral tablet 26
 BOSULIF ORAL CAPSULE 100 MG, 50
 MG 12, 14
 BOSULIF ORAL TABLET 100 MG, 400
 MG, 500 MG..... 12, 14
 BRAFTOVI ORAL CAPSULE 75 MG .. 12,
 14
 BRUKINSA ORAL CAPSULE 12, 14
 BRUKINSA ORAL TABLET..... 12, 14
 budesonide inhalation suspension 0.25
 mg/2ml, 0.5 mg/2ml, 1 mg/2ml 257
 butalbital-acetaminophen oral tablet 50-325
 mg 88
 butalbital-apap-caff-cod oral capsule 50-
 325-40-30 mg..... 88
 butalbital-apap-caffeine oral capsule 50-
 325-40 mg 88
 butalbital-apap-caffeine oral solution 88
 butalbital-apap-caffeine oral tablet 50-325-
 40 mg 88
 butalbital-asa-caff-codeine..... 88
 butalbital-aspirin-caffeine oral capsule..... 88
C
 CABLIVI 27
 CABOMETYX 12, 14
 calcium acetate (phos binder) oral capsule
 667 mg 257
 calcium acetate (phos binder) oral tablet 667
 mg 257
 CALQUENCE ORAL TABLET 12, 14
 CAMZYOS 28, 29
 CAPLYTA 138, 139
 CAPRELSA ORAL TABLET 100 MG, 300
 MG 12, 14
 carglumic acid oral tablet soluble 30
 carisoprodol oral 90
 caspofungin acetate 31
 CAYSTON..... 22

CEPROTIN 32
 CERDELGA 33
 CHENODAL..... 34
 chlorzoxazone oral tablet 500 mg 90
 CHOLBAM..... 35
 CIBINQO 36, 37
 CIMZIA (2 SYRINGE) 38, 39
 CIMZIA SUBCUTANEOUS KIT 2 X 200
 MG 38, 39
 CIMZIA-STARTER 38, 39
 CINRYZE 83, 84
 CLINISOL SF INTRAVENOUS
 SOLUTION 15 % 257
 clomipramine hcl oral 86
 COBENFY 138, 139
 COBENFY STARTER PACK 138, 139
 COMETRIQ (100 MG DAILY DOSE)
 ORAL KIT 80 & 20 MG 12, 14
 COMETRIQ (140 MG DAILY DOSE)
 ORAL KIT 3 X 20 MG & 80 MG .. 12, 14
 COMETRIQ (60 MG DAILY DOSE) 12, 14
 COPIKTRA..... 12, 14
 CORLANOR ORAL SOLUTION..... 40
 CORTROPHIN 41
 CORTROPHIN GEL 41
 COSENTYX (300 MG DOSE)..... 42
 COSENTYX INTRAVENOUS..... 42
 COSENTYX SENSOREADY (300 MG). 42
 COSENTYX SENSOREADY PEN 42
 COSENTYX SUBCUTANEOUS
 SOLUTION PREFILLED SYRINGE 150
 MG/ML, 75 MG/0.5ML 42
 COSENTYX UNOREADY 42
 COTELLIC 12, 14
 CRESEMBA ORAL 43
 cromolyn sodium inhalation nebulization
 solution 20 mg/2ml 257
 CRYSVITA..... 44
 CUVRIOR..... 214
 cyclobenzaprine hcl oral tablet 10 mg, 5 mg
 90
 cyclophosphamide oral capsule 25 mg, 50
 mg 257
 cyclophosphamide oral tablet 25 mg, 50 mg
 257

cyclosporine modified oral capsule 100 mg,
25 mg, 50 mg 257
cyclosporine modified oral solution 100
mg/ml 257
cyclosporine oral capsule 100 mg, 25 mg 257
cyproheptadine hcl oral 86
CYSTAGON 45
CYSTARAN 46
D
dalfampridine er 47
DANZITEN 12, 14
dasatinib 12, 14
DAURISMO ORAL TABLET 100 MG, 25
MG 12, 14
deferasirox 48
deferasirox granules 48
deferiprone 49
deflazacort 50
DIACOMIT ORAL CAPSULE 250 MG,
500 MG 51
DIACOMIT ORAL PACKET 250 MG, 500
MG 51
dihydroergotamine mesylate nasal 52
dimethyl fumarate oral capsule delayed
release 120 mg, 240 mg 121, 122
dimethyl fumarate starter pack oral capsule
delayed release therapy pack 121, 122
diphenoxylate-atropine oral liquid 86
diphenoxylate-atropine oral tablet 2.5-0.025
mg 86
dipyridamole oral 86
DOPTLET 53
doxepin hcl external 54
doxepin hcl oral capsule 86
doxepin hcl oral concentrate 86
dronabinol oral capsule 10 mg, 2.5 mg, 5 mg
..... 257
droxidopa oral capsule 100 mg, 200 mg, 300
mg 55
DUPIXENT SUBCUTANEOUS
SOLUTION AUTO-INJECTOR 200
MG/1.14ML, 300 MG/2ML 56
DUPIXENT SUBCUTANEOUS
SOLUTION PREFILLED SYRINGE 200
MG/1.14ML, 300 MG/2ML 56

E
EGRIFTA SV 57
EGRIFTA WR 57
ELIGARD 80
eltrombopag olamine oral packet 12.5 mg,
25 mg 160
eltrombopag olamine oral tablet 12.5 mg, 25
mg, 50 mg, 75 mg 160
EMEND ORAL SUSPENSION
RECONSTITUTED 125 MG/5ML 257
EMGALITY 58
EMGALITY (300 MG DOSE) 58
EMSAM 59
ENBREL MINI 60
ENBREL SUBCUTANEOUS SOLUTION
25 MG/0.5ML 60
ENBREL SUBCUTANEOUS SOLUTION
PREFILLED SYRINGE 60
ENBREL SURECLICK SUBCUTANEOUS
SOLUTION AUTO-INJECTOR 60
ENGERIX-B INJECTION SUSPENSION
20 MCG/ML 257
ENGERIX-B INJECTION SUSPENSION
PREFILLED SYRINGE 10 MCG/0.5ML,
20 MCG/ML 257
ENSACOVE 12, 14
ENTYVIO PEN 62
ENVARUS XR ORAL TABLET
EXTENDED RELEASE 24 HOUR 0.75
MG, 1 MG, 4 MG 257
EPIDIOLEX 63
EPOGEN INJECTION SOLUTION 10000
UNIT/ML, 2000 UNIT/ML, 20000
UNIT/ML, 3000 UNIT/ML, 4000
UNIT/ML 65
ergotamine-caffeine 86
ERIVEDGE 12, 14
ERLEADA ORAL TABLET 240 MG, 60
MG 12, 14
erlotinib hcl oral tablet 100 mg, 150 mg, 25
mg 12, 14
ERZOFRI INTRAMUSCULAR
SUSPENSION PREFILLED SYRINGE
117 MG/0.75ML, 156 MG/ML, 234
MG/1.5ML, 351 MG/2.25ML, 39
MG/0.25ML, 78 MG/0.5ML 66

eszopiclone..... 91
 EUCRISA 67
 EULEXIN 12, 14
 everolimus oral tablet 0.25 mg, 0.5 mg, 0.75
 mg, 1 mg 257
 everolimus oral tablet 10 mg, 2.5 mg, 5 mg,
 7.5 mg 12, 14
 everolimus oral tablet soluble 12, 14
 EVRYSOI ORAL SOLUTION
 RECONSTITUTED 68
 EVRYSOI ORAL TABLET 68
F
 FABHALTA 69
 FANAPT 138, 139
 FANAPT TITRATION PACK A ... 138, 139
 FANAPT TITRATION PACK B ORAL
 TABLET 138, 139
 FANAPT TITRATION PACK C ORAL
 TABLET 138, 139
 FASENRA PEN..... 70, 71
 FASENRA SUBCUTANEOUS
 SOLUTION PREFILLED SYRINGE 10
 MG/0.5ML, 30 MG/ML 70, 71
 fentanyl transdermal patch 72 hour 100
 mcg/hr 85
 FILSPARI 72
 fingolimod hcl..... 121, 122
 FINTEPLA..... 73
 FIRDAPSE..... 74
 FIRMAGON (240 MG DOSE)..... 80
 FIRMAGON SUBCUTANEOUS
 SOLUTION RECONSTITUTED 80 MG
 80
 flucytosine oral..... 75
 formoterol fumarate inhalation nebulization
 solution 20 mcg/2ml 257
 FOTIVDA 12, 14
 FRUZAQLA ORAL CAPSULE 1 MG, 5
 MG 12, 14
 FULPHILA 236, 237
 fulvestrant intramuscular solution prefilled
 syringe..... 76
 FYLNETRA..... 236, 237
G
 GALAFOLD 77

GAMMAGARD INJECTION SOLUTION
 1 GM/10ML, 10 GM/100ML, 2.5
 GM/25ML, 20 GM/200ML, 30
 GM/300ML, 5 GM/50ML 257
 GAMMAGARD S/D LESS IGA
 INTRAVENOUS SOLUTION
 RECONSTITUTED 10 GM, 5 GM.... 257
 GAMMAKED INJECTION SOLUTION 1
 GM/10ML 257
 GAMMAPLEX INTRAVENOUS
 SOLUTION 10 GM/100ML, 10
 GM/200ML, 20 GM/200ML, 5
 GM/50ML 257
 GAMUNEX-C INJECTION SOLUTION 1
 GM/10ML 257
 GATTEX..... 78
 GAVRETO 12, 14
 gefitinib 12, 14
 GENGRAF ORAL CAPSULE 100 MG, 25
 MG 257
 GENOTROPIN MINIQUICK
 SUBCUTANEOUS PREFILLED
 SYRINGE 82
 GENOTROPIN SUBCUTANEOUS
 CARTRIDGE..... 82
 GILOTRIF 12, 14
 GLASSIA..... 9
 glatiramer acetate subcutaneous solution
 prefilled syringe 20 mg/ml, 40 mg/ml 121,
 122
 GLATOPA SUBCUTANEOUS
 SOLUTION PREFILLED SYRINGE 20
 MG/ML, 40 MG/ML 121, 122
 GOCOVRI ORAL CAPSULE EXTENDED
 RELEASE 24 HOUR 137 MG, 68.5 MG
 81
 GOMEKLI 12, 14
 granisetron hcl oral tablet 1 mg 257
H
 HAEGARDA SUBCUTANEOUS
 SOLUTION RECONSTITUTED 2000
 UNIT, 3000 UNIT 83, 84
 HEPLISAV-B INTRAMUSCULAR
 SOLUTION PREFILLED SYRINGE 20
 MCG/0.5ML 257
 HERNEXEOS..... 12, 14

HETLIOZ LQ 199
hydroxyzine hcl oral syrup..... 86
hydroxyzine hcl oral tablet..... 86
hydroxyzine pamoate oral..... 86
HYFTOR..... 92
I
IBRANCE 12, 14
IBTROZI..... 12, 14
icatibant acetate subcutaneous solution
 prefilled syringe 93
ICLUSIG 12, 14
IDHIFA 12, 14
ILARIS SUBCUTANEOUS SOLUTION 94
ILUMYA..... 95
imatinib mesylate oral tablet 100 mg, 400
 mg 12, 14
IMBRUVICA ORAL CAPSULE 140 MG,
 70 MG 96
IMBRUVICA ORAL SUSPENSION..... 96
IMBRUVICA ORAL TABLET 140 MG,
 280 MG, 420 MG..... 96
imipramine hcl oral 86
imipramine pamoate oral capsule 100 mg,
 125 mg, 150 mg, 75 mg 86
imkeldi 12, 14
IMOVAX RABIES INTRAMUSCULAR
 SUSPENSION RECONSTITUTED 2.5
 UNIT/ML 257
IMPAVIDO..... 97
IMULDOSA SUBCUTANEOUS
 SOLUTION PREFILLED SYRINGE 45
 MG/0.5ML, 90 MG/ML 221, 222
INCRELEX..... 98
INGREZZA ORAL CAPSULE 229
INGREZZA ORAL CAPSULE SPRINKLE
 229
INGREZZA ORAL CAPSULE THERAPY
 PACK..... 229
INLYTA ORAL TABLET 1 MG, 5 MG. 12,
 14
INQOVI 12, 14
INREBIC..... 12, 14
INTRALIPID INTRAVENOUS
 EMULSION 20 %, 30 % 257
ipratropium bromide inhalation solution
 0.02 % 257

ipratropium-albuterol inhalation solution
 0.5-2.5 (3) mg/3ml 257
ITOVEBI..... 12, 14
ivabradine hcl oral tablet 5 mg, 7.5 mg 40
IWILFIN 12, 14
J
JAKAFI..... 99
JAYPIRCA ORAL TABLET 100 MG, 50
 MG 12, 14
JUXTAPID ORAL CAPSULE 10 MG, 20
 MG, 30 MG, 5 MG 100
JYLAMVO 116
K
KALYDECO..... 101
KERENDIA 102
KESIMPTA..... 121, 122
KEVZARA 103
KINERET SUBCUTANEOUS SOLUTION
 PREFILLED SYRINGE 104
KISQALI (200 MG DOSE)..... 12, 14
KISQALI (400 MG DOSE)..... 12, 14
KISQALI (600 MG DOSE)..... 12, 14
KISQALI FEMARA (400 MG DOSE) ... 12,
 14
KISQALI FEMARA (600 MG DOSE) ... 12,
 14
KOSELUGO ORAL CAPSULE 12, 14
KRAZATI..... 12, 14
L
lanthanum carbonate oral tablet chewable
 1000 mg, 500 mg, 750 mg 258
lapatinib ditosylate 12, 14
LAZCLUZE 12, 14
lenalidomide..... 12, 14
LENVIMA (10 MG DAILY DOSE) .. 12, 14
LENVIMA (12 MG DAILY DOSE) .. 12, 14
LENVIMA (14 MG DAILY DOSE) .. 12, 14
LENVIMA (18 MG DAILY DOSE) .. 12, 14
LENVIMA (20 MG DAILY DOSE) .. 13, 14
LENVIMA (24 MG DAILY DOSE) .. 13, 14
LENVIMA (4 MG DAILY DOSE) 13, 14
LENVIMA (8 MG DAILY DOSE) 13, 14
LEQSELVI 105
LEUKERAN 13, 14
LEUKINE INJECTION SOLUTION
 RECONSTITUTED 236, 237

leuprolide acetate (3 month) 80
 leuprolide acetate injection 80
 levalbuterol hcl inhalation nebulization
 solution 0.31 mg/3ml, 0.63 mg/3ml, 1.25
 mg/3ml 258
 l-glutamine oral packet 61
 lidocaine external patch 5 % 212
 liraglutide 79
 LITFULO 106
 LIVMARLI 107, 108
 LIVTENCITY 109
 LODOCO 110
 lofexidine hcl 111
 LONSURF 13, 14
 LORBRENA ORAL TABLET 100 MG, 25
 MG 13, 14
 LUMAKRAS 13, 14
 LUPKYNIS 112
 LUPRON DEPOT (1-MONTH) 80
 LUPRON DEPOT (3-MONTH) 80
 LUPRON DEPOT (4-MONTH) 80
 LUPRON DEPOT (6-MONTH) 80
 LUTRATE DEPOT 80
 LYBALVI 113, 114
 LYNPARZA ORAL TABLET 13, 14
 LYTGABI (12 MG DAILY DOSE) ... 13, 14
 LYTGABI (16 MG DAILY DOSE) ... 13, 14
 LYTGABI (20 MG DAILY DOSE) ... 13, 14
M
 MAVENCLAD (10 TABS) 121, 122
 MAVENCLAD (4 TABS) 121, 122
 MAVENCLAD (5 TABS) 121, 122
 MAVENCLAD (6 TABS) 121, 122
 MAVENCLAD (7 TABS) 121, 122
 MAVENCLAD (8 TABS) 121, 122
 MAVENCLAD (9 TABS) 121, 122
 MAVYRET ORAL PACKET 115
 MAVYRET ORAL TABLET 115
 MAYZENT 121, 122
 MAYZENT STARTER PACK ORAL
 TABLET THERAPY PACK 12 X 0.25
 MG, 7 X 0.25 MG 121, 122
 megestrol acetate oral suspension 40 mg/ml,
 400 mg/10ml, 625 mg/5ml 89
 megestrol acetate oral tablet 89

MEKINIST ORAL SOLUTION
 RECONSTITUTED 13, 14
 MEKINIST ORAL TABLET 0.5 MG, 2
 MG 13, 14
 MEKTOVI 13, 14
 mercaptopurine oral suspension 13, 14
 metaxalone oral tablet 800 mg 90
 methadone hcl oral tablet 10 mg 85
 methocarbamol oral tablet 500 mg, 750 mg
 90
 methyltestosterone oral 117
 metyrosine 118
 mifepristone oral tablet 300 mg 119
 miglustat 120
 modafinil oral tablet 100 mg, 200 mg 126
 MODEYSO 13, 14
 morphine sulfate er oral tablet extended
 release 100 mg, 200 mg 85
 mycophenolate mofetil oral capsule 250 mg
 258
 mycophenolate mofetil oral suspension
 reconstituted 200 mg/ml 258
 mycophenolate mofetil oral tablet 500 mg
 258
 mycophenolate sodium oral tablet delayed
 release 180 mg, 360 mg 258
 MYFEMBREE 123
N
 NAYZILAM 124
 NERLYNX 13, 14
 NEULASTA ONPRO SUBCUTANEOUS
 SOLUTION PREFILLED SYRINGE 236,
 237
 NEULASTA SUBCUTANEOUS
 SOLUTION PREFILLED SYRINGE 236,
 237
 NEXLETOL 2, 3
 NEXLIZET 2, 3
 NGENLA 82
 nifedipine oral 86
 nilotinib d-tartrate oral capsule 150 mg, 200
 mg, 50 mg 13, 14
 nilotinib hcl oral capsule 150 mg, 200 mg,
 50 mg 13, 14
 nilutamide 13, 14
 NINLARO 13, 14

nitisinone..... 125
 NUBEQA..... 13, 14
 NUCALA SUBCUTANEOUS SOLUTION
 AUTO-INJECTOR 127
 NUCALA SUBCUTANEOUS SOLUTION
 PREFILLED SYRINGE 100 MG/ML, 40
 MG/0.4ML 127
 NUCALA SUBCUTANEOUS SOLUTION
 RECONSTITUTED 127
 NUEDEXTA..... 128
 NUPLAZID ORAL CAPSULE..... 129
 NUPLAZID ORAL TABLET 10 MG.... 129
 NURTEC..... 130
 NUTRILIPID INTRAVENOUS
 EMULSION 20 %..... 258
O
 OCALIVA..... 131, 132
 OCREVUS..... 133
 octreotide acetate injection solution 100
 mcg/ml, 1000 mcg/ml, 200 mcg/ml, 50
 mcg/ml, 500 mcg/ml 134
 octreotide acetate intramuscular 134
 ODOMZO 13, 14
 OFEV 135, 136
 OGSIVEO ORAL TABLET 100 MG, 150
 MG, 50 MG..... 13, 14
 OJEMDA 13, 14
 OJJAARA 13, 14
 OMNITROPE SUBCUTANEOUS
 SOLUTION CARTRIDGE..... 82
 OMNITROPE SUBCUTANEOUS
 SOLUTION RECONSTITUTED 82
 ondansetron hcl oral solution 4 mg/5ml.. 258
 ondansetron hcl oral tablet 24 mg, 4 mg, 8
 mg 258
 ondansetron oral tablet dispersible 4 mg, 8
 mg 258
 ONUREG..... 13, 14
 OPIPZA ORAL FILM 10 MG, 2 MG, 5 MG
 138, 139
 OPSUMIT 137
 ORENCIA CLICKJECT..... 140, 141
 ORENCIA INTRAVENOUS 140, 141
 ORENCIA SUBCUTANEOUS SOLUTION
 PREFILLED SYRINGE 125 MG/ML, 50
 MG/0.4ML, 87.5 MG/0.7ML 140, 141

ORFADIN ORAL SUSPENSION..... 125
 ORGOVYX..... 13, 14
 ORIAHNN 142
 ORILISSA..... 143, 144
 ORKAMBI ORAL PACKET 145
 ORKAMBI ORAL TABLET 145
 ORLADEYO..... 83, 84
 ORSERDU ORAL TABLET 345 MG, 86
 MG 13, 14
 OTEZLA ORAL TABLET..... 146
 OTEZLA ORAL TABLET THERAPY
 PACK..... 146
 OXERVATE 147
 OXYCONTIN ORAL TABLET ER 12
 HOUR ABUSE-DETERRENT 10 MG,
 15 MG, 20 MG, 30 MG, 40 MG, 60 MG,
 80 MG 148, 149
 OZEMPIC (0.25 OR 0.5 MG/DOSE)
 SUBCUTANEOUS SOLUTION PEN-
 INJECTOR 2 MG/3ML 79
 OZEMPIC (1 MG/DOSE)
 SUBCUTANEOUS SOLUTION PEN-
 INJECTOR 4 MG/3ML 79
 OZEMPIC (2 MG/DOSE) 79
P
 PANRETIN..... 210
 pazopanib hcl 13, 14
 PEGASYS SUBCUTANEOUS SOLUTION
 180 MCG/ML 152
 PEGASYS SUBCUTANEOUS SOLUTION
 PREFILLED SYRINGE 152
 PEMAZYRE 13, 14
 penicillamine oral tablet..... 153
 pentamidine isethionate inhalation solution
 reconstituted 300 mg..... 258
 PERSERIS 154
 phenobarbital oral elixir 20 mg/5ml 87
 phenobarbital oral tablet 87
 phenoxybenzamine hcl oral 155
 PIQRAY (200 MG DAILY DOSE).... 13, 14
 PIQRAY (250 MG DAILY DOSE).... 13, 14
 PIQRAY (300 MG DAILY DOSE).... 13, 14
 pirfenidone oral capsule..... 156
 pirfenidone oral tablet 267 mg, 534 mg, 801
 mg 156

PLENAMINE INTRAVENOUS
 SOLUTION 15 % 258
 POMALYST 13, 14
 PONVORY 121, 122
 PONVORY STARTER PACK..... 121, 122
 posaconazole oral suspension 157
 posaconazole oral tablet delayed release 157
 PREHEVBRIO INTRAMUSCULAR
 SUSPENSION 10 MCG/ML 258
 pretomanid 158
 PREVYMIS ORAL 159
 PRIVIGEN INTRAVENOUS SOLUTION
 10 GM/100ML, 20 GM/200ML, 40
 GM/400ML, 5 GM/50ML 258
 PROCIT..... 65
 PROGRAF INTRAVENOUS SOLUTION 5
 MG/ML 258
 PROGRAF ORAL PACKET 0.2 MG, 1 MG
 258
 PROLASTIN-C INTRAVENOUS
 SOLUTION..... 9
 promethazine-phenylephrine..... 86
 PULMOZYME INHALATION
 SOLUTION 2.5 MG/2.5ML 258
 pyrimethamine oral 161
 PYRUKYND 162, 163
 PYRUKYND TAPER PACK..... 162, 163
Q
 QINLOCK..... 13, 14
 QULIPTA 164
R
 RABAVERT INTRAMUSCULAR
 SUSPENSION RECONSTITUTED... 258
 RADICAVA ORS..... 165
 RADICAVA ORS STARTER KIT 165
 RAVICTI 166
 REBIF REBIDOSE SUBCUTANEOUS
 SOLUTION AUTO-INJECTOR 121, 122
 REBIF REBIDOSE TITRATION PACK
 SUBCUTANEOUS SOLUTION AUTO-
 INJECTOR..... 121, 122
 REBIF SUBCUTANEOUS SOLUTION
 PREFILLED SYRINGE 121, 122
 REBIF TITRATION PACK
 SUBCUTANEOUS SOLUTION
 PREFILLED SYRINGE 121, 122

RECOMBIVAX HB INJECTION
 SUSPENSION 10 MCG/ML, 40
 MCG/ML, 5 MCG/0.5ML 258
 RECOMBIVAX HB INJECTION
 SUSPENSION PREFILLED SYRINGE
 10 MCG/ML, 5 MCG/0.5ML 258
 RECORLEV 167
 RELISTOR ORAL..... 168
 RELISTOR SUBCUTANEOUS
 SOLUTION 12 MG/0.6ML, 12
 MG/0.6ML (0.6ML SYRINGE), 8
 MG/0.4ML 168
 RELISTOR SUBCUTANEOUS
 SOLUTION PREFILLED SYRINGE 12
 MG/0.6ML, 8 MG/0.4ML 168
 REPATHA 150, 151
 REPATHA SURECLICK..... 150, 151
 RETACRIT INJECTION SOLUTION
 10000 UNIT/ML, 10000
 UNIT/ML(1ML), 2000 UNIT/ML, 20000
 UNIT/ML, 3000 UNIT/ML, 4000
 UNIT/ML, 40000 UNIT/ML 65
 RETEVMO ORAL TABLET 120 MG, 160
 MG, 40 MG, 80 MG 13, 14
 REVCovi..... 169
 REVLIMID 13, 14
 REVUFORJ 13, 14
 REXULTI 170
 REZDIFFRA..... 171, 172
 REZLIDHIA 13, 14
 REZUROCK..... 173
 ROMVIMZA 13, 14
 ROZLYTREK ORAL CAPSULE 100 MG,
 200 MG 13, 14
 ROZLYTREK ORAL PACKET 13, 14
 RUBRACA 13, 14
 rufinamide oral suspension 174
 rufinamide oral tablet..... 174
 RYBELSUS 79
 RYDAPT..... 13, 14
 RYKINDO 175
 RYLAZE..... 176
S
 sapropterin dihydrochloride oral packet . 177
 sapropterin dihydrochloride oral tablet... 177

SCEMBLIX ORAL TABLET 100 MG, 20 MG, 40 MG..... 13, 14
 SECUADO..... 178
 SELARSDI INTRAVENOUS 221, 222
 SELARSDI SUBCUTANEOUS
 SOLUTION PREFILLED SYRINGE 45 MG/0.5ML, 90 MG/ML 221, 222
 SEROSTIM SUBCUTANEOUS
 SOLUTION RECONSTITUTED 4 MG, 5 MG, 6 MG..... 179
 sevelamer carbonate oral packet 0.8 gm, 2.4 gm 258
 sevelamer carbonate oral tablet 800 mg.. 258
 SIGNIFOR 180
 sildenafil citrate oral suspension reconstituted..... 181
 sildenafil citrate oral tablet 20 mg 181
 SILIQ 182
 SIMLANDI (1 PEN) SUBCUTANEOUS
 AUTO-INJECTOR KIT 40 MG/0.4ML, 80 MG/0.8ML 6
 SIMLANDI (1 SYRINGE) 6
 SIMLANDI (2 PEN)..... 6
 SIMLANDI (2 SYRINGE)
 SUBCUTANEOUS PREFILLED SYRINGE KIT 20 MG/0.2ML, 40 MG/0.4ML 6
 SIMPONI SUBCUTANEOUS SOLUTION
 AUTO-INJECTOR 100 MG/ML, 50 MG/0.5ML 183, 184
 SIMPONI SUBCUTANEOUS SOLUTION
 PREFILLED SYRINGE 100 MG/ML, 50 MG/0.5ML 183, 184
 sirolimus oral solution 1 mg/ml 258
 sirolimus oral tablet 0.5 mg, 1 mg, 2 mg 258
 SIRTURO 185
 SKYTROFA SUBCUTANEOUS
 CARTRIDGE 11 MG, 13.3 MG, 3 MG, 3.6 MG, 4.3 MG, 5.2 MG, 6.3 MG, 7.6 MG, 9.1 MG..... 82
 sodium oxybate 186
 sodium phenylbutyrate oral powder 3 gm/tsp 187
 sodium phenylbutyrate oral tablet..... 187
 sofosbuvir-velpatasvir 188
 SOLTAMOX 13, 14

SOMAVERT..... 189
 sorafenib tosylate 13, 14
 SOTYKTU 190
 STELARA INTRAVENOUS 221, 222
 STELARA SUBCUTANEOUS
 SOLUTION 45 MG/0.5ML 221, 222
 STELARA SUBCUTANEOUS
 SOLUTION PREFILLED SYRINGE 45 MG/0.5ML, 90 MG/ML 221, 222
 STEQEYMA INTRAVENOUS 221, 222
 STEQEYMA SUBCUTANEOUS
 SOLUTION PREFILLED SYRINGE 45 MG/0.5ML, 90 MG/ML 221, 222
 STIVARGA 13, 14
 SUCRAID 191
 sunitinib malate 13, 14
 SYMDEKO..... 192
 SYNAREL 193
T
 TABLOID 13, 14
 TABRECTA 13, 14
 tacrolimus oral capsule 0.5 mg, 1 mg, 5 mg 258
 tadalafil (pah)..... 194
 tadalafil oral tablet 5 mg 195
 TADLIQ..... 194
 TAFINLAR ORAL CAPSULE 13, 14
 TAFINLAR ORAL TABLET SOLUBLE13, 14
 TAGRISSO 13, 14
 TALTZ SUBCUTANEOUS SOLUTION
 AUTO-INJECTOR 196, 197
 TALTZ SUBCUTANEOUS SOLUTION
 PREFILLED SYRINGE 20 MG/0.25ML, 40 MG/0.5ML, 80 MG/ML 196, 197
 TALZENNA 13, 14
 TARPEYO 198
 TASCENSO ODT..... 121, 122
 tasimeleuton 199
 TAVNEOS..... 200, 201
 TAZVERIK..... 13, 14
 temazepam 91
 TENIVAC INTRAMUSCULAR
 INJECTABLE 5-2 LFU, 5-2 LFU (INJECTION) 258

TENIVAC INTRAMUSCULAR
 SUSPENSION 5-2 LF/0.5ML 258
 TEPEZZA 202
 TEPMETKO 13, 14
 teriflunomide..... 121, 122
 teriparatide subcutaneous solution pen-
 injector 560 mcg/2.24ml 203
 testosterone cypionate intramuscular
 solution 100 mg/ml, 200 mg/ml, 200
 mg/ml (1 ml) 204
 testosterone enanthate intramuscular
 solution..... 205
 testosterone transdermal gel 1.62 %, 12.5
 mg/act (1%), 20.25 mg/1.25gm (1.62%),
 20.25 mg/act (1.62%), 25 mg/2.5gm
 (1%), 40.5 mg/2.5gm (1.62%), 50
 mg/5gm (1%) 211
 testosterone transdermal solution..... 211
 tetrabenazine 229
 THALOMID ORAL CAPSULE 100 MG,
 50 MG 13, 14
 TIBSOVO 13, 14
 tigecycline 207
 tiopronin oral..... 206
 TOBI PODHALER..... 208
 tobramycin inhalation nebulization solution
 300 mg/4ml, 300 mg/5ml..... 258
 tolvaptan (hyponatremia)..... 209
 tolvaptan oral tablet 15 mg, 30 mg 209
 tolvaptan oral tablet therapy pack 209
 topiramate oral solution 64
 toremifene citrate 13, 14
 TRELSTAR MIXJECT 80
 TREMFYA CROHNS INDUCTION 213
 TREMFYA ONE-PRESS
 SUBCUTANEOUS SOLUTION PEN-
 INJECTOR..... 213
 TREMFYA PEN SUBCUTANEOUS
 SOLUTION AUTO-INJECTOR 100
 MG/ML, 200 MG/2ML 213
 TREMFYA SUBCUTANEOUS
 SOLUTION PREFILLED SYRINGE 100
 MG/ML, 200 MG/2ML 213
 TREMFYA-CD/UC INDUCTION..... 213
 tretinoin oral..... 13, 14
 trientine hcl oral capsule 250 mg..... 214

TRIKAFTA ORAL TABLET THERAPY
 PACK..... 215
 TRIKAFTA ORAL THERAPY PACK.. 215
 TRUQAP..... 13, 14
 TUKYSA ORAL TABLET 150 MG, 50
 MG 13, 14
 TURALIO ORAL CAPSULE 125 MG... 13,
 14
 TYMLOS 216
 TYVASO DPI MAINTENANCE KIT
 INHALATION POWDER 16 MCG, 32
 MCG, 48 MCG, 64 MCG 217, 218
 TYVASO DPI TITRATION KIT
 INHALATION POWDER 16 & 32 & 48
 MCG 217, 218
U
 UBRELVY..... 219
 UPTRAVI ORAL 220
 UPTRAVI TITRATION..... 220
 ustekinumab subcutaneous solution 221, 222
 ustekinumab subcutaneous solution prefilled
 syringe 45 mg/0.5ml, 90 mg/ml.. 221, 222
 ustekinumab-aekn subcutaneous solution
 prefilled syringe 45 mg/0.5ml, 90 mg/ml
 221, 222
 UZEDY SUBCUTANEOUS SUSPENSION
 PREFILLED SYRINGE 100
 MG/0.28ML, 125 MG/0.35ML, 150
 MG/0.42ML, 200 MG/0.56ML, 250
 MG/0.7ML, 50 MG/0.14ML, 75
 MG/0.21ML 223
V
 VALCHLOR..... 224
 VALTOCO 10 MG DOSE..... 124
 VALTOCO 15 MG DOSE NASAL
 LIQUID THERAPY PACK 2 X 7.5
 MG/0.1ML 124
 VALTOCO 20 MG DOSE NASAL
 LIQUID THERAPY PACK 2 X 10
 MG/0.1ML 124
 VALTOCO 5 MG DOSE..... 124
 VANFLYTA 13, 14
 VEMLIDY 225
 VENCLEXTA ORAL TABLET 10 MG,
 100 MG, 50 MG..... 13, 14
 VENCLEXTA STARTING PACK 13, 14

VEOZAH	226
VERZENIO.....	13, 14
vigabatrin	227
VIGAFYDE	227
VIJOICE ORAL PACKET	228
VIJOICE ORAL TABLET THERAPY PACK 125 MG, 200 & 50 MG, 50 MG	228
VITRAKVI ORAL CAPSULE 100 MG, 25 MG	13, 14
VITRAKVI ORAL SOLUTION	13, 14
VIZIMPRO	13, 14
VONJO	13, 14
VOQUEZNA	230
VOQUEZNA DUAL PAK	230
VOQUEZNA TRIPLE PAK.....	230
VORANIGO	13, 14
voriconazole intravenous	231
voriconazole oral.....	231
VOSEVI.....	232
VOWST	233
VRAYLAR ORAL CAPSULE.....	138, 139
VYNDAMAX.....	234
W	
WEGOVY SUBCUTANEOUS SOLUTION AUTO-INJECTOR 0.25 MG/0.5ML, 0.5 MG/0.5ML, 1 MG/0.5ML, 1.7 MG/0.75ML, 2.4 MG/0.75ML	235
WELIREG.....	13, 14
WINREVAIR.....	238
X	
XALKORI ORAL CAPSULE.....	13, 14
XALKORI ORAL CAPSULE SPRINKLE 150 MG, 20 MG, 50 MG	14
XATMEP	116
XDEMVI	239
XELJANZ ORAL SOLUTION	240
XELJANZ ORAL TABLET.....	240
XELJANZ XR	240
XERMELO	241
XIAFLEX	242
XIFAXAN ORAL TABLET 200 MG, 550 MG	243
XOLAIR	244
XOLREMDI	245
XOSPATA	14

XPOVIO (100 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 50 MG	14
XPOVIO (40 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 10 MG, 40 MG	14
XPOVIO (40 MG TWICE WEEKLY) ORAL TABLET THERAPY PACK 40 MG	14
XPOVIO (60 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 60 MG....	14
XPOVIO (60 MG TWICE WEEKLY).....	14
XPOVIO (80 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 40 MG....	14
XPOVIO (80 MG TWICE WEEKLY).....	14
XTANDI ORAL CAPSULE.....	14
XTANDI ORAL TABLET 40 MG, 80 MG	14
XYWAV	246
Y	
YESINTEK INTRAVENOUS.....	221, 222
YESINTEK SUBCUTANEOUS SOLUTION.....	221, 222
YESINTEK SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 45 MG/0.5ML, 90 MG/ML	221, 222
YONSA.....	14
YORVIPATH	247
YUTREPIA.....	248, 249
Z	
zaleplon	91
ZARXIO	236, 237
ZAVZPRET	250
ZEJULA ORAL TABLET.....	14
ZELBORAF.....	14
ZEMAIRA	9
ZEPBOUND SUBCUTANEOUS SOLUTION AUTO-INJECTOR	251, 252
ZEPOSIA	253
ZEPOSIA 7-DAY STARTER PACK.....	253
ZEPOSIA STARTER KIT ORAL CAPSULE THERAPY PACK 0.23MG &0.46MG 0.92MG(21).....	253
ZILBRYSQ SUBCUTANEOUS SOLUTION PREFILLED SYRINGE	

16.6 MG/0.416ML, 23 MG/0.574ML,
 32.4 MG/0.81ML 254
 ZOLINZA 14
 zolpidem tartrate er 91
 zolpidem tartrate oral tablet 91
 ZTALMY 255

ZTLIDO 212
 ZURZUVAE ORAL CAPSULE 20 MG, 25
 MG, 30 MG..... 256
 ZYDELIG 14
 ZYKADIA ORAL TABLET 14